Materiały źródłowe

• #1 Current Management and Emerging Therapies in Multiple System Atrophy

  https://pmc.ncbi.nlm.nih.gov/articles/PMC7851250/

  Multiple system atrophy (MSA) is a progressive neurodegenerative disease variably associated with motor, nonmotor, and autonomic symptoms, resulting from putaminal and cerebellar degeneration and associated with glial cytoplasmic inclusions enriched with -synuclein in oligodendrocytes and neurons. […] Although symptomatic treatment of MSA can provide significant improvements in quality of life, the benefit is often partial, limited by adverse effects, and fails to treat the underlying cause. […] Research into disease-modifying therapies is ongoing with a particular focus on synuclein-targeted therapies among others. […] Currently available lab tests or imaging do not provide additional diagnostic or prognostic sensitivity or specificity beyond that of a thorough clinical assessment. […] There are currently no approved disease-modifying therapies, although research in a variety of mechanistically driven areas is ongoing and the patient should be given the opportunity to participate in clinical trials.

• #2

  https://link.springer.com/article/10.1007/s13311-020-00890-x

  Multiple system atrophy (MSA) is a progressive neurodegenerative disease variably associated with motor, nonmotor, and autonomic symptoms, resulting from putaminal and cerebellar degeneration and associated with glial cytoplasmic inclusions enriched with -synuclein in oligodendrocytes and neurons. […] Although symptomatic treatment of MSA can provide significant improvements in quality of life, the benefit is often partial, limited by adverse effects, and fails to treat the underlying cause. […] Treatment is best achieved through a coordinated multidisciplinary approach driven by the patients priorities and goals of care. […] Research into disease-modifying therapies is ongoing with a particular focus on synuclein-targeted therapies among others. […] There are currently no approved disease-modifying therapies, although research in a variety of mechanistically driven areas is ongoing and the patient should be given the opportunity to participate in clinical trials.

• #3 Multiple System Atrophy Treatment & Management: Approach Considerations, Nonpharmacologic Treatment of Hypotension and Hypertension

  https://emedicine.medscape.com/article/1154583-treatment

  The cause of multiple system atrophy (MSA) remains unknown, and no current therapy can reverse or halt progression of the disease. The extrapyramidal and cerebellar aspects of the disease are debilitating and difficult to treat. […] Drug therapy is directed mainly toward alleviation of symptoms of the movement disorder and orthostatic hypotension. Urinary incontinence, constipation, erectile dysfunction, and supine hypertension can also be addressed through pharmacologic therapy. […] An atrial pacemaker may be used in patients with profound bradycardia in addition to orthostatic hypotension as a means of preventing the hypotension. However, this treatment is rarely undertaken and is rarely helpful. […] Mechanical maneuvers, such as leg-crossing, squatting, abdominal compression, bending forward, and placing 1 foot on a chair, can be effective in preventing episodes of orthostatic hypotension.

• #4 Multiple system atrophy – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/multiple-system-atrophy/diagnosis-treatment/drc-20356157

  Medicines to reduce Parkinson’s disease-like symptoms. Medicines that treat Parkinson’s disease, such as combined levodopa and carbidopa (Sinemet, Duopa, others), can help some people with MSA. The medicine can treat stiffness, trouble with balance and slow movements. Many people with multiple system atrophy do not respond to Parkinson’s medicines. The medicines also may become less effective after a few years. […] Medicines to treat erection problems. If you have trouble getting or keeping an erection, you can be treated with medicines such as sildenafil (Revatio, Viagra). This medicine helps manage erectile dysfunction but it can lower blood pressure. […] Steps to manage swallowing and breathing symptoms. If you have trouble swallowing, try eating softer foods. If swallowing or breathing symptoms become worse, you might need surgery to insert a feeding or breathing tube. A gastrostomy tube delivers food directly into your stomach. If you have sleep apnea, you might be treated with continuous positive airway pressure (CPAP) or bilevel positive airway pressure (BiPAP). Stridor also can be treated with CPAP.

• #5 Multiple System Atrophy Medication: Antiparkinson Agents, COMT Inhibitors, Antiparkinson Agents, Dopamine Agonists, Antiparkinson Agents, Anticholinergics, Urinary Antispasmodic Agents, Prokinetic Agents, Agents for Erectile Dysfunction, Corticosteroids,

  https://emedicine.medscape.com/article/1154583-medication

  As previously mentioned, pharmacologic therapy for multiple system atrophy (MSA) is directed mainly toward alleviation of symptoms of the movement disorder and orthostatic hypotension. Medications can also be used to treat urinary incontinence, constipation, erectile dysfunction, and supine hypertension. […] The movement-disorder component of MSA is usually treated with levodopa, dopaminergic agonists, anticholinergic agents, or amantadine, but results are rarely as favorable in MSA as in classic Parkinson disease. […] Many agents have been advocated for the management of orthostatic hypotension. […] In February 2014, droxidopa was approved by the FDA for the treatment of orthostatic hypotension. It is a synthetic amino precursor prodrug and is converted to norepinephrine. […] Water is a uniquely powerful pressor agent in the management of orthostatic hypotension in patients with MSA.

• #6

  https://movementdisorders.ufhealth.org/for-patients/movement-disorder-information/multiple-system-atrophy-primer-many-faces-same-disease/

  Treatment of MSA remains largely supportive. About 30-60% of patients respond to typical Parkinsons medications such as carbidopa/levodopa (Sinemet), and dose trial of up to 1 gram/day of levodopa for a few months is recommended. Benefit seen early in disease often fades though, or becomes fraught with complications. […] More advanced motor symptoms, such as muscle spasm or fixed postures (dystonia), can be treated with muscle relaxants and sometimes by injection of botulinum toxin (i.e., Botox). […] Physical and occupational therapies for gait and balance, range of motion and mobility, and help with activities of daily living are critical and require staff familiar with Parkinsonian patient needs. […] Treatment initially begins with conservative therapies including increased fluid intake, salt in diet (considering of course any concomitant heart disease), and wearing pressure stockings or binder. If these are not enough, drug treatment may be necessary. Options include blood volume increasers (fludrocortisone) or pressor agents (e.g., midodrine). Both increase BP thereby reducing episodes of low BP, but the later can also cause excessive high BP usually when lying down. Careful monitoring of BP is needed, avoiding ups and downs, and a happy medium found for each individual. Urinary and bowel symptoms likewise can be treated with select agents depending on the issue. Sleep disturbance can also be successfully treated depending on cause.

• #7

  https://link.springer.com/article/10.1007/s13311-020-00890-x

  To date there are no approved disease-modifying therapies for MSA; thus, treatment is focused mainly on symptom management tailored to the specific patient and importantly involves a multidisciplinary approach with rehab and other allied healthcare partners. […] While ideal, multidisciplinary care for MSA and other neurodegenerative disorders faces challenges in delivery. […] Nearly a third of MSA-P patients benefit from levodopa therapy, but temporarily with mean duration of 3.5 years in one study. […] Dopamine agonists may be used as a second choice, but lack supporting evidence and are generally not preferred because of their increased side effect profile relative to levodopa. […] Nonpharmacological approaches such as physical, occupational, and speech therapy are both complementary and essential therapies in MSA.

• #8 Multiple system atrophy – Wikipedia

  https://en.wikipedia.org/wiki/Multiple_system_atrophy

  Levodopa (L-Dopa), a drug used in the treatment of Parkinson’s disease, improves parkinsonian symptoms in a small percentage of MSA patients. A recent trial reported that only 1.5% of MSA patients experienced any improvement at all when taking levodopa, their improvement was less than 50%, and even that improvement was a transient effect lasting less than one year. Poor response to L-Dopa has been suggested as a possible element in the differential diagnosis of MSA from Parkinson’s disease. […] Management by rehabilitation professionals including physiatrists, physiotherapists, occupational therapists, speech therapists, and others for difficulties with walking/movement, daily tasks, and speech problems is essential. […] Physiotherapists can help to maintain the patient’s mobility and will help to prevent contractures.

• #9 Emerging Therapies For Multiple System Atrophy Treatment

  https://www.delveinsight.com/blog/multiple-system-atrophy-treatment

  Other drugs used to treat Parkinsons disease, in addition to levodopa, may be used to treat multiple system atrophy patients. These included dopamine agonists like ropinirole (Requip) and pramipexole (Mirapexin), which boost dopamine receptor activation in the brain. This aids the brains reception of dopamine messages. Midodrine hydrochloride (ProAmatine) has been used to treat low blood pressure, which has been linked to multiple system atrophy in certain cases. Low blood pressure can be treated using adrenergic medications such as ephedrine. Low blood pressure can also be treated with L-threo-dihydroxyphenylserine (L-DOPS or Lthreo-DOPS). […] Midodrine is thought to be more physiologic and well-tolerated than fludrocortisone, and other medicines worth testing include indomethacin and intranasal desmopressin. The breadth of treatment options for orthostatic hypotension in multiple system atrophy provides clinicians with some hope of alleviating the misery of many patients. Multiple system atrophy covers the major market with off-label and generic treatments. Clonazepam, vitamin E, propanolol, baclofen, or amantadine have demonstrated superior efficacy. However, in an open-label experiment with MSA-C patients, buspirone (off-label) improved upper-limb ataxia. Depending on the severity of the other symptoms, drugs such as sildenafil (Viagra), tadalafil (Cialis), or vardenafil (Levitra) may be used to treat urinary and erectile dysfunction (ED) symptoms that are common in males with multiple system atrophy.

• #10

  https://link.springer.com/article/10.1007/s13311-020-00890-x

  To date there are no approved disease-modifying therapies for MSA; thus, treatment is focused mainly on symptom management tailored to the specific patient and importantly involves a multidisciplinary approach with rehab and other allied healthcare partners. […] While ideal, multidisciplinary care for MSA and other neurodegenerative disorders faces challenges in delivery. […] Nearly a third of MSA-P patients benefit from levodopa therapy, but temporarily with mean duration of 3.5 years in one study. […] Dopamine agonists may be used as a second choice, but lack supporting evidence and are generally not preferred because of their increased side effect profile relative to levodopa. […] Nonpharmacological approaches such as physical, occupational, and speech therapy are both complementary and essential therapies in MSA.

• #11 Multiple System Atrophy Medication: Antiparkinson Agents, COMT Inhibitors, Antiparkinson Agents, Dopamine Agonists, Antiparkinson Agents, Anticholinergics, Urinary Antispasmodic Agents, Prokinetic Agents, Agents for Erectile Dysfunction, Corticosteroids,

  https://emedicine.medscape.com/article/1154583-medication

  As previously mentioned, pharmacologic therapy for multiple system atrophy (MSA) is directed mainly toward alleviation of symptoms of the movement disorder and orthostatic hypotension. Medications can also be used to treat urinary incontinence, constipation, erectile dysfunction, and supine hypertension. […] The movement-disorder component of MSA is usually treated with levodopa, dopaminergic agonists, anticholinergic agents, or amantadine, but results are rarely as favorable in MSA as in classic Parkinson disease. […] Many agents have been advocated for the management of orthostatic hypotension. […] In February 2014, droxidopa was approved by the FDA for the treatment of orthostatic hypotension. It is a synthetic amino precursor prodrug and is converted to norepinephrine. […] Water is a uniquely powerful pressor agent in the management of orthostatic hypotension in patients with MSA.

• #12 Multiple System Atrophy Symptoms and Causes

  https://www.verywellhealth.com/multiple-system-atrophy-2860862

  Currently, there is no cure for MSA, nor are there any treatments specifically designed to reverse or stop disease progression. Some aspects of the disorder are debilitating and difficult to treat. Treatments may include: […] Levodopa and carbidopa (Sinemet) for movement disorders, but they usually have limited results […] Trihexyphenidyl, benztropine mesylate (Cogentin), and amantadine (Symmetrel) […] Botulinum toxin (commonly known as botox) injections to ease abnormal muscle postures (dystonia) […] Fludrocortisone, midodrine, and droxidopa for orthostatic hypertension […] Physical and occupational therapy, including aqua therapy, can help maintain muscle function […] Speech therapy to improve difficulties swallowing or speaking.

• #13 Emerging Therapies For Multiple System Atrophy Treatment

  https://www.delveinsight.com/blog/multiple-system-atrophy-treatment

  In the approved market segment for multiple system atrophy treatment, NORTHERA (droxidopa) is the worlds first approved medication for symptomatic nOH. Dainippon Sumitomo Pharma (DSP) developed it first, and it was commercialized in Japan in 1989. In 2006, Chelsea Therapeutics International acquired the medication license from DSP. Chelsea received fast clearance for NORTHERA from the US FDA in February 2014 for symptomatic benefit in adult patients with nOH, and exclusivity expires in February 2021. nOH is found in around 66-90% of multiple system atrophy patients and is a leading source of disability and injury in the disease. There is currently no approved disease-modifying agent. The drug used to treat Parkinsons disease, most notably levodopa (SINEMET), is also administered for multiple system atrophy patients. The efficacy of such drugs, however, varies substantially across affected individuals.

• #14 Multiple system atrophy – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/multiple-system-atrophy/diagnosis-treatment/drc-20356157

  Treatment for multiple system atrophy (MSA) involves managing your symptoms. There’s no cure for MSA. Managing the disease can make you as comfortable as possible and help you maintain your body functions. […] To treat specific symptoms, your healthcare team may recommend: […] Medicines to raise blood pressure. These medicines can treat low blood pressure that happens when standing after sitting or lying down, known as postural hypotension. There are several medicines your healthcare professional may recommend. The corticosteroid fludrocortisone can increase blood pressure by helping your body retain more salt and water. Midodrine (Orvaten) can raise your blood pressure quickly. This medicine needs to be taken carefully because it can increase blood pressure while lying down. Don’t lie flat for four hours after taking this medicine. The medicine pyridostigmine (Mestinon, Regonol) can raise your blood pressure while standing without causing a large increase when you’re lying down. Another medicine called droxidopa (Northera) also treats postural hypotension. The most common side effects of droxidopa include headaches, dizziness and nausea.

• #15 Multiple System Atrophy Treatment & Management: Approach Considerations, Nonpharmacologic Treatment of Hypotension and Hypertension

  https://emedicine.medscape.com/article/1154583-treatment

  The management of patients with orthostatic hypotension and supine hypertension can be challenging, but adequate BP control is often achieved with the following treatment strategy: Use of over-the-counter medication with pressor effects, avoidance of fluid intake at bedtime, not using elastic stockings when supine, not using pressor agents before bedtime, raising the head of the bed 6-9 inches, resting on a semirecumbent chair with feet on the floor during the day, snacking before bedtime. […] Increased salt and fluid intake maintains plasma volume. Small, frequent meals may help patients for whom postprandial hypotension is a significant problem. […] Exercise of muscles of the lower extremities and abdomen, water aerobics at hip level (not swimming, as it causes polyuria), and postural training, in combination with drug therapy, are useful.

• #16 What can I expect with Parkinson’s/MSA? How do you cope as a caregiver? – AgingCare.com

  https://www.agingcare.com/questions/what-can-i-expect-with-parkinsons-and-msa-how-do-you-cope-as-a-caregiver-474189.htm

• #17 Known Treatments – Defeat MSA New Zealand Trust

  https://defeatmsa.org.nz/what-is-msa/known-treatments/

  Compression stockings have been shown be an effective treatment for OH by increasing venous return. […] Supplementation with coenzyme Q10 has also shown promise to treat the symptoms of OH. […] Pharmaceutical treatments for nOH try to either increase plasma volume or to increase peripheral resistance through various mechanisms of action. […] Drugs used to treat MSA are described in Table 1. […] Midodrine has been shown to be effective in the treatment of nOH among MSA patients, with an increase in standing systolic BP of nearly 22mg Hg. […] Non-pharmacologic treatment of Parkinson-like symptoms of MSA include A regular schedule of physical and occupational therapies can help to control the parkinsonian symptoms of MSA. […] Dietary modifications can enhance the effects of certain classes of medication used to treat Parkinson-like symptoms in MSA.

• #18 Multiple System Atrophy

  https://neurosciences.ucsd.edu/centers-programs/movement-disorders/community/disease-overview/msa.html

  While there is no cure for MSA, we work to control and alleviate symptoms of the disease to avoid complications and to improve the quality of patients’ lives. […] At UC San Diego Health, we use a multidisciplinary management approach for MSA. Along with a movement disorder specialist, a urologist, physical, speech, and occupational therapists and dietitians are involved in the management plan. […] For orthostatic hypotension, measures can be taken to prevent it, including: rising slowly from supine to sitting position, raising the head of the bed 20 to 30 degrees with a furniture raiser, and increasing daily salt and water intake. Using custom-fitted elastic stockings that extend to the waist or readjusting medication can help maintain blood pressure and prevent significant drops. Abdominal bands are also beneficial.

• #19 Multiple System Atrophy Treatment & Management: Approach Considerations, Nonpharmacologic Treatment of Hypotension and Hypertension

  https://emedicine.medscape.com/article/1154583-treatment

  The management of patients with orthostatic hypotension and supine hypertension can be challenging, but adequate BP control is often achieved with the following treatment strategy: Use of over-the-counter medication with pressor effects, avoidance of fluid intake at bedtime, not using elastic stockings when supine, not using pressor agents before bedtime, raising the head of the bed 6-9 inches, resting on a semirecumbent chair with feet on the floor during the day, snacking before bedtime. […] Increased salt and fluid intake maintains plasma volume. Small, frequent meals may help patients for whom postprandial hypotension is a significant problem. […] Exercise of muscles of the lower extremities and abdomen, water aerobics at hip level (not swimming, as it causes polyuria), and postural training, in combination with drug therapy, are useful.

• #20 Multiple System Atrophy (MSA): Symptoms, Diagnosis, Treatment

  https://www.webmd.com/brain/what-is-multiple-system-atrophy

  Medications can help with erectile dysfunction if that becomes a problem for you. […] Steps you can take to make yourself more comfortable include: […] Eat more salt, drink more water, and have caffeine to raise your blood pressure […] Wear compression stockings […] Avoid standing up too quickly […] Sleep with the head of your bed raised […] Eat more fiber, take stool softeners, or try enemas for constipation […] Keep yourself from getting overheated […] Move around as much as you can to keep blood clots from forming.

• #21 What can I expect with Parkinson’s/MSA? How do you cope as a caregiver? – AgingCare.com

  https://www.agingcare.com/questions/what-can-i-expect-with-parkinsons-and-msa-how-do-you-cope-as-a-caregiver-474189.htm

• #22 Multiple System Atrophy Treatment & Management: Approach Considerations, Nonpharmacologic Treatment of Hypotension and Hypertension

  https://emedicine.medscape.com/article/1154583-treatment

  The cause of multiple system atrophy (MSA) remains unknown, and no current therapy can reverse or halt progression of the disease. The extrapyramidal and cerebellar aspects of the disease are debilitating and difficult to treat. […] Drug therapy is directed mainly toward alleviation of symptoms of the movement disorder and orthostatic hypotension. Urinary incontinence, constipation, erectile dysfunction, and supine hypertension can also be addressed through pharmacologic therapy. […] An atrial pacemaker may be used in patients with profound bradycardia in addition to orthostatic hypotension as a means of preventing the hypotension. However, this treatment is rarely undertaken and is rarely helpful. […] Mechanical maneuvers, such as leg-crossing, squatting, abdominal compression, bending forward, and placing 1 foot on a chair, can be effective in preventing episodes of orthostatic hypotension.

• #23 Multiple System Atrophy Treatment & Management: Approach Considerations, Nonpharmacologic Treatment of Hypotension and Hypertension

  https://emedicine.medscape.com/article/1154583-treatment

  The management of patients with orthostatic hypotension and supine hypertension can be challenging, but adequate BP control is often achieved with the following treatment strategy: Use of over-the-counter medication with pressor effects, avoidance of fluid intake at bedtime, not using elastic stockings when supine, not using pressor agents before bedtime, raising the head of the bed 6-9 inches, resting on a semirecumbent chair with feet on the floor during the day, snacking before bedtime. […] Increased salt and fluid intake maintains plasma volume. Small, frequent meals may help patients for whom postprandial hypotension is a significant problem. […] Exercise of muscles of the lower extremities and abdomen, water aerobics at hip level (not swimming, as it causes polyuria), and postural training, in combination with drug therapy, are useful.

• #24 Multiple system atrophy – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/multiple-system-atrophy/diagnosis-treatment/drc-20356157

  Treatment for multiple system atrophy (MSA) involves managing your symptoms. There’s no cure for MSA. Managing the disease can make you as comfortable as possible and help you maintain your body functions. […] To treat specific symptoms, your healthcare team may recommend: […] Medicines to raise blood pressure. These medicines can treat low blood pressure that happens when standing after sitting or lying down, known as postural hypotension. There are several medicines your healthcare professional may recommend. The corticosteroid fludrocortisone can increase blood pressure by helping your body retain more salt and water. Midodrine (Orvaten) can raise your blood pressure quickly. This medicine needs to be taken carefully because it can increase blood pressure while lying down. Don’t lie flat for four hours after taking this medicine. The medicine pyridostigmine (Mestinon, Regonol) can raise your blood pressure while standing without causing a large increase when you’re lying down. Another medicine called droxidopa (Northera) also treats postural hypotension. The most common side effects of droxidopa include headaches, dizziness and nausea.

• #25 Multiple System Atrophy (MSA) – Neurologic Disorders – Merck Manual Professional Edition

  https://www.merckmanuals.com/professional/neurologic-disorders/autonomic-nervous-system/multiple-system-atrophy-msa

  There is no specific treatment for multiple system atrophy, but symptoms are managed as follows: […] Treatment includes intravascular volume expansion with salt and water supplementation and sometimes fludrocortisone. Use of compression garments for the lower body (eg, abdominal binder, compression stockings) and alpha-adrenoreceptor stimulation with midodrine may help. […] Levodopa/carbidopa may be tried to relieve rigidity and other parkinsonian symptoms, but this combination may be ineffective or provide only modest benefit. […] If the cause is detrusor hyperreflexia, oxybutynin chloride or tolterodine may be used. Tamsulosin may be effective for urinary urgency. Alternatively, the beta-3 adrenergic agonist mirabegron can be used; unlike tamsulosin, mirabegron does not worsen orthostatic hypotension.

• #26 Multiple system atrophy – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/multiple-system-atrophy/diagnosis-treatment/drc-20356157

  Treatment for multiple system atrophy (MSA) involves managing your symptoms. There’s no cure for MSA. Managing the disease can make you as comfortable as possible and help you maintain your body functions. […] To treat specific symptoms, your healthcare team may recommend: […] Medicines to raise blood pressure. These medicines can treat low blood pressure that happens when standing after sitting or lying down, known as postural hypotension. There are several medicines your healthcare professional may recommend. The corticosteroid fludrocortisone can increase blood pressure by helping your body retain more salt and water. Midodrine (Orvaten) can raise your blood pressure quickly. This medicine needs to be taken carefully because it can increase blood pressure while lying down. Don’t lie flat for four hours after taking this medicine. The medicine pyridostigmine (Mestinon, Regonol) can raise your blood pressure while standing without causing a large increase when you’re lying down. Another medicine called droxidopa (Northera) also treats postural hypotension. The most common side effects of droxidopa include headaches, dizziness and nausea.

• #27 Multiple System Atrophy Medication: Antiparkinson Agents, COMT Inhibitors, Antiparkinson Agents, Dopamine Agonists, Antiparkinson Agents, Anticholinergics, Urinary Antispasmodic Agents, Prokinetic Agents, Agents for Erectile Dysfunction, Corticosteroids,

  https://emedicine.medscape.com/article/1154583-medication

  The management of patients with orthostatic hypotension and supine hypertension can be challenging, but adequate BP control is often achieved by combining the nonpharmacologic approach, as previously described, with the following medications: nitrates, transdermal nitroglycerin, hydralazine, nifedipine, and clonidine. […] Patients with MSA may have an initial response to levodopa, but this response usually diminishes over time. […] Midodrine is a prodrug with activity as an alpha1-adrenoreceptor agonist. This agent is widely used to treat orthostatic hypotension in MSA. […] Droxidopa is an oral norepinephrine precursor that is directly metabolized to norepinephrine by dopa-decarboxylase which is extensively distributed throughout the body. […] Epoetin alfa has been shown to increase the functional capacity of patients with MSA, particularly those with characteristic mild anemia. […] Indomethacin inhibits vasodilator prostaglandin synthesis. […] Diphenhydramine is a first-generation antihistamine with anticholinergic effects that binds to H1 receptors in the CNS and body.

• #28 Multiple System Atrophy Medication: Antiparkinson Agents, COMT Inhibitors, Antiparkinson Agents, Dopamine Agonists, Antiparkinson Agents, Anticholinergics, Urinary Antispasmodic Agents, Prokinetic Agents, Agents for Erectile Dysfunction, Corticosteroids,

  https://emedicine.medscape.com/article/1154583-medication

  The management of patients with orthostatic hypotension and supine hypertension can be challenging, but adequate BP control is often achieved by combining the nonpharmacologic approach, as previously described, with the following medications: nitrates, transdermal nitroglycerin, hydralazine, nifedipine, and clonidine. […] Patients with MSA may have an initial response to levodopa, but this response usually diminishes over time. […] Midodrine is a prodrug with activity as an alpha1-adrenoreceptor agonist. This agent is widely used to treat orthostatic hypotension in MSA. […] Droxidopa is an oral norepinephrine precursor that is directly metabolized to norepinephrine by dopa-decarboxylase which is extensively distributed throughout the body. […] Epoetin alfa has been shown to increase the functional capacity of patients with MSA, particularly those with characteristic mild anemia. […] Indomethacin inhibits vasodilator prostaglandin synthesis. […] Diphenhydramine is a first-generation antihistamine with anticholinergic effects that binds to H1 receptors in the CNS and body.

• #29 Multiple System Atrophy Research Program | NYU Langone Health

  https://med.nyu.edu/departments-institutes/neurology/research/divisions-centers/autonomic-disorders/multiple-system-atrophy-research-program

  The Division of Autonomic Disorders, in conjunction with NYU Langones Dysautonomia Center, leads a comprehensive clinical research program dedicated to multiple system atrophy (MSA). As a world-class reference center for MSA, the Multiple System Atrophy Research Program provides direct access to clinical care and support to more than 100 people living with MSA. […] We offer patients the opportunity to participate in research studies focused on understanding the causes and evolution of MSA; developing and approving new symptomatic treatments of MSA; and discovering treatments that can stop or slow the progression of neurodegeneration in MSA. […] NYU Langones Dysautonomia Center has a long history of developing and helping approve drugs for the symptomatic treatment of MSA. In the last 10 years, researchers at our center have led the development and approval of midodrine and droxidopa (Northera), two drugs now used for the treatment of orthostatic hypotension in people who have MSA.

• #30 Multiple system atrophy – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/multiple-system-atrophy/diagnosis-treatment/drc-20356157

  Treatment for multiple system atrophy (MSA) involves managing your symptoms. There’s no cure for MSA. Managing the disease can make you as comfortable as possible and help you maintain your body functions. […] To treat specific symptoms, your healthcare team may recommend: […] Medicines to raise blood pressure. These medicines can treat low blood pressure that happens when standing after sitting or lying down, known as postural hypotension. There are several medicines your healthcare professional may recommend. The corticosteroid fludrocortisone can increase blood pressure by helping your body retain more salt and water. Midodrine (Orvaten) can raise your blood pressure quickly. This medicine needs to be taken carefully because it can increase blood pressure while lying down. Don’t lie flat for four hours after taking this medicine. The medicine pyridostigmine (Mestinon, Regonol) can raise your blood pressure while standing without causing a large increase when you’re lying down. Another medicine called droxidopa (Northera) also treats postural hypotension. The most common side effects of droxidopa include headaches, dizziness and nausea.

• #31 Multiple System Atrophy-D Maybe Something Altogether–Different

  https://practicalneurology.com/articles/2018-mar-apr/multiple-system-atrophy-d-maybe-something-altogetherdifferent

  The 6th International Congress on Multi-system Atrophy met in March, 2018 in New York City and focused on continuing to establish multisystem atrophy (MSA) as a separate, unique disease with unique pathology, diagnostic hurdles, and nuanced treatment. […] MSA is not as responsive to treatment, and the clinical course of worsening symptoms seems accelerated compared to PD. […] Medications to treat orthostatic hypotension, including fludrocortisone, midodrine, pyridostigmine, and droxidopa, have targeted increasing blood volume or peripheral vascular tone. […] As presented at the conference, droxidopa increases vagal tone via effects on norepinephrine receptors. Combination therapy including pyridostigmine and atomoxetine is under investigation. […] Abdominal binders may be more beneficial than compression stockings because most orthostatic blood pooling occurs in abdomen.

• #32 Multiple System Atrophy Medication: Antiparkinson Agents, COMT Inhibitors, Antiparkinson Agents, Dopamine Agonists, Antiparkinson Agents, Anticholinergics, Urinary Antispasmodic Agents, Prokinetic Agents, Agents for Erectile Dysfunction, Corticosteroids,

  https://emedicine.medscape.com/article/1154583-medication

  The management of patients with orthostatic hypotension and supine hypertension can be challenging, but adequate BP control is often achieved by combining the nonpharmacologic approach, as previously described, with the following medications: nitrates, transdermal nitroglycerin, hydralazine, nifedipine, and clonidine. […] Patients with MSA may have an initial response to levodopa, but this response usually diminishes over time. […] Midodrine is a prodrug with activity as an alpha1-adrenoreceptor agonist. This agent is widely used to treat orthostatic hypotension in MSA. […] Droxidopa is an oral norepinephrine precursor that is directly metabolized to norepinephrine by dopa-decarboxylase which is extensively distributed throughout the body. […] Epoetin alfa has been shown to increase the functional capacity of patients with MSA, particularly those with characteristic mild anemia. […] Indomethacin inhibits vasodilator prostaglandin synthesis. […] Diphenhydramine is a first-generation antihistamine with anticholinergic effects that binds to H1 receptors in the CNS and body.

• #33

  https://link.springer.com/article/10.1007/s13311-020-00890-x

  Although historically thought to have limited cognitive impairment compared to other atypical syndromes and Parkinson disease, recent evidence indicates the presence of cognitive dysfunction and dementia estimated in 14 to 16% of MSA patients causing significant impact on quality of life. […] The management of orthostatic hypotension begins with behavioral or lifestyle changes including increased fluid and salt intake (i.e., volume expansion), wearing compression stockings or an abdominal binder, and being mindful of exacerbating conditions such as activity in hot, humid weather. […] Urinary dysfunction is the most common autonomic symptom of MSA and is recognized as a diagnostic criterion. […] Erectile dysfunction is a key criterion for diagnosis of probable MSA in men and, given the social stigma and patient embarrassment, is likely underreported.

• #34 Multiple System Atrophy (MSA) – Neurologic Disorders – Merck Manual Professional Edition

  https://www.merckmanuals.com/professional/neurologic-disorders/autonomic-nervous-system/multiple-system-atrophy-msa

  There is no specific treatment for multiple system atrophy, but symptoms are managed as follows: […] Treatment includes intravascular volume expansion with salt and water supplementation and sometimes fludrocortisone. Use of compression garments for the lower body (eg, abdominal binder, compression stockings) and alpha-adrenoreceptor stimulation with midodrine may help. […] Levodopa/carbidopa may be tried to relieve rigidity and other parkinsonian symptoms, but this combination may be ineffective or provide only modest benefit. […] If the cause is detrusor hyperreflexia, oxybutynin chloride or tolterodine may be used. Tamsulosin may be effective for urinary urgency. Alternatively, the beta-3 adrenergic agonist mirabegron can be used; unlike tamsulosin, mirabegron does not worsen orthostatic hypotension.

• #35 Multiple system atrophy | Monash Health

  https://monashhealth.org/services/movement-disorders-program/understanding-movement-disorders/multiple-system-atrophy/

  Treatment for bladder incontinence include: Medications such as oxybutynin, Intermittent self-catheterisation. […] Medications and several practical solutions can be used to improve low blood pressure, which includes: Medications such as fludrocortisone, midodrine and droxidopa, Drinking adequate fluids, High salt diet, Eating small and frequent meals over the day, Pressure stockings, Raising the head of the bed when sleeping. […] Breathing disorders, such as sleep apnoea, may require a face mask to be worn at night through which a continuous positive air pressure is applied to keep the upper airways open. […] If the sleep disorder rapid eye movement sleep behaviour disorder (RBD) is severe enough, medications such as melatonin may relieve the symptoms. […] Depression can be managed effectively with a range of antidepressants.

• #36 Multiple System Atrophy (MSA) – Neurologic Disorders – Merck Manual Professional Edition

  https://www.merckmanuals.com/professional/neurologic-disorders/autonomic-nervous-system/multiple-system-atrophy-msa

  There is no specific treatment for multiple system atrophy, but symptoms are managed as follows: […] Treatment includes intravascular volume expansion with salt and water supplementation and sometimes fludrocortisone. Use of compression garments for the lower body (eg, abdominal binder, compression stockings) and alpha-adrenoreceptor stimulation with midodrine may help. […] Levodopa/carbidopa may be tried to relieve rigidity and other parkinsonian symptoms, but this combination may be ineffective or provide only modest benefit. […] If the cause is detrusor hyperreflexia, oxybutynin chloride or tolterodine may be used. Tamsulosin may be effective for urinary urgency. Alternatively, the beta-3 adrenergic agonist mirabegron can be used; unlike tamsulosin, mirabegron does not worsen orthostatic hypotension.

• #37 Multiple System Atrophy (MSA) – Neurologic Disorders – Merck Manual Professional Edition

  https://www.merckmanuals.com/professional/neurologic-disorders/autonomic-nervous-system/multiple-system-atrophy-msa

  There is no specific treatment for multiple system atrophy, but symptoms are managed as follows: […] Treatment includes intravascular volume expansion with salt and water supplementation and sometimes fludrocortisone. Use of compression garments for the lower body (eg, abdominal binder, compression stockings) and alpha-adrenoreceptor stimulation with midodrine may help. […] Levodopa/carbidopa may be tried to relieve rigidity and other parkinsonian symptoms, but this combination may be ineffective or provide only modest benefit. […] If the cause is detrusor hyperreflexia, oxybutynin chloride or tolterodine may be used. Tamsulosin may be effective for urinary urgency. Alternatively, the beta-3 adrenergic agonist mirabegron can be used; unlike tamsulosin, mirabegron does not worsen orthostatic hypotension.

• #38 Multiple system atrophy – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/multiple-system-atrophy/diagnosis-treatment/drc-20356157

  Bladder care. If you have trouble with bladder control, medicines can help in the earlier stages. But as MSA gets worse, you may need to have a soft tube inserted to drain your bladder. The soft tube is known as a catheter. […] Therapy. A physical therapist can help you maintain as much of your movement and strength as possible as the disease gets worse. A speech-language pathologist can help you improve or maintain your speech.

• #39 Multiple System Atrophies (MSA)

  https://www.healthline.com/health/neurological-health/multiple-system-atrophy

  During the early stages of incontinence, your doctor may prescribe medications to help you control problems. During later stages, your doctor may recommend the insertion of a permanent catheter to allow you to pass urine comfortably. […] If youre experiencing difficulty swallowing, your doctor may recommend that you eat softer foods. If swallowing or breathing become difficult, your doctor may recommend surgically inserting a feeding or breathing tube to make these activities easier. In the later stages of MSA, your doctor may recommend a feeding tube that goes directly to your stomach. […] Through gentle exercise and repeated motion, physical therapy may help you maintain muscle strength and motor skills for as long as possible while MSA progresses. Speech-language therapy may also help you to maintain speech.

• #40 Multiple System Atrophy (MSA) – Brain, Spinal Cord, and Nerve Disorders – Merck Manual Consumer Version

  https://www.merckmanuals.com/home/brain-spinal-cord-and-nerve-disorders/autonomic-nervous-system-disorders/multiple-system-atrophy-msa

  Fludrocortisone may be taken by mouth. It helps the body retain salt and water and thus may increase blood pressure as needed when a person stands. Other medications, such as midodrine or droxidopa, taken by mouth, may also help. […] If sweating is reduced or absent, people should avoid warm environments to avoid overheating the body. Good dental care and regular check-ups are essential for people with dry mouth. Artificial tears (eye drops containing substances that resemble real tears) applied every few hours may relieve dry eyes. […] If needed, people can learn to insert a catheter (a thin rubber tube) into the bladder themselves. […] Sometimes medications such as bethanechol are used to stimulate contractions of the bladder and thus help the bladder empty. […] Oxybutynin, mirabegron, tamsulosin, or tolterodine, taken by mouth, may be used to relax the muscles of an overactive bladder.

• #41

  https://link.springer.com/article/10.1007/s13311-020-00890-x

  Deep brain stimulation for parkinsonism in MSA is not recommended as symptoms often poorly respond and rapidly progress relative to Parkinson disease. […] Medical therapies for dystonia including benzodiazepines and anticholinergics are not commonly used because of cognitive and respiratory risks. […] There are currently no medications available that provide evidence-supported improvement in ataxic symptoms in MSA. […] Sleep disorders are common in MSA and include insomnia, daytime somnolence, restless legs syndrome (RLS), REM sleep behavior disorder (RBD), and sleep disordered breathing. […] Despite the frequency and severity of depression and anxiety in patients with MSA with up to half of patients reporting symptoms and evidence they play a major role in quality of life, randomized controlled trials providing therapeutic guidance are lacking.

• #42 Multiple system atrophy – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/multiple-system-atrophy/diagnosis-treatment/drc-20356157

  Medicines to reduce Parkinson’s disease-like symptoms. Medicines that treat Parkinson’s disease, such as combined levodopa and carbidopa (Sinemet, Duopa, others), can help some people with MSA. The medicine can treat stiffness, trouble with balance and slow movements. Many people with multiple system atrophy do not respond to Parkinson’s medicines. The medicines also may become less effective after a few years. […] Medicines to treat erection problems. If you have trouble getting or keeping an erection, you can be treated with medicines such as sildenafil (Revatio, Viagra). This medicine helps manage erectile dysfunction but it can lower blood pressure. […] Steps to manage swallowing and breathing symptoms. If you have trouble swallowing, try eating softer foods. If swallowing or breathing symptoms become worse, you might need surgery to insert a feeding or breathing tube. A gastrostomy tube delivers food directly into your stomach. If you have sleep apnea, you might be treated with continuous positive airway pressure (CPAP) or bilevel positive airway pressure (BiPAP). Stridor also can be treated with CPAP.

• #43 Multiple System Atrophy-D Maybe Something Altogether–Different

  https://practicalneurology.com/articles/2018-mar-apr/multiple-system-atrophy-d-maybe-something-altogetherdifferent

  Continuous positive airway pressure (CPAP) is the first-line treatment for stridor. […] If motor symptoms are a contributing factor to sleep disorders, maximize dopaminergic medications. […] First-line treatment for bladder dysfunction is usually anticholinergics, but a newer class of 3-adrenergic agonists are being utilized as they have little to no central cognitive impact. […] Posterior tibial nerve stimulation is also being explored as potential treatment for bladder dysfunction in patients with MSA and PD. […] For the latter, currently in phase 2 trials, TD-9855 is being studied for the treatment of neurogenic orthostatic hypotension, as a daily-dose compound with vasogenic tone properties. […] For disease modification, studies of possible therapies run the gamut from autophagy, to active immunization, vaccination, and stem cells.

• #44 Known Treatments – Defeat MSA New Zealand Trust

  https://defeatmsa.org.nz/what-is-msa/known-treatments/

  Non-pharmacologic treatment of sexual dysfunction include: Cognitive therapy to treat underlying depression and anxiety that is common among MSA patients. […] Medications used to treat sexual dysfunction include: PDE-5 inhibitors, including sildenafil, increase blood flow to the penis and have been proven to treat ED in patients with MSA. […] Non-pharmacologic treatment of REM behavior disorder include: Ensuring bedroom safety to prevent injury includes lowering the bed, padding bedside furniture and removing firearms is an important aspect to managing RBD. […] Medications used to help with REM behavior disorder include: Clonazepam, a benzodiazepine, has been shown to reduce frequency and severity and prevent injury in RBD. […] Non-pharmacologic treatment of psychiatric issues include: Cognitive therapy can not only help manage the mental health symptoms associated with MSA, it has also been shown to increase memory, help slow down cognitive decline, and decrease fall risk in patients with MSA.

• #45 Multiple System Atrophy (MSA) | Movement Disorders Clinic

  https://www.movementdisordersclinic.com/multiple-system-atrophy-msa/

  Sleep problems such as REM sleep behavior disorder can be treated with medicines including clonazepam, melatonin, or some antidepressants. […] Some individuals with MSA may have significant difficulties with swallowing and may need a feeding tube or nutritional support. Speech therapy may be helpful in identifying strategies to address swallowing difficulties. […] Physical therapy helps maintain mobility, reduce contractures (chronic shortening of muscles or tendons around joints, which prevents the joints from moving freely), and decrease muscle spasms and abnormal posture. […] Individuals may eventually need assistive devices such as walkers and wheelchairs. Occupational therapists help with home safety and learning new ways to address activities of daily living such as dressing and eating.

• #46 Multiple system atrophy | Monash Health

  https://monashhealth.org/services/movement-disorders-program/understanding-movement-disorders/multiple-system-atrophy/

  Treatment for bladder incontinence include: Medications such as oxybutynin, Intermittent self-catheterisation. […] Medications and several practical solutions can be used to improve low blood pressure, which includes: Medications such as fludrocortisone, midodrine and droxidopa, Drinking adequate fluids, High salt diet, Eating small and frequent meals over the day, Pressure stockings, Raising the head of the bed when sleeping. […] Breathing disorders, such as sleep apnoea, may require a face mask to be worn at night through which a continuous positive air pressure is applied to keep the upper airways open. […] If the sleep disorder rapid eye movement sleep behaviour disorder (RBD) is severe enough, medications such as melatonin may relieve the symptoms. […] Depression can be managed effectively with a range of antidepressants.

• #47 Multiple System Atrophy

  https://neurosciences.ucsd.edu/centers-programs/movement-disorders/community/disease-overview/msa.html

  When these measures are insufficient, medications such as fludrocortisone that retain salt, or midodrine that increase the blood pressure may be needed. […] Bladder function should be evaluated by a urologist, usually requiring a urodynamic study that allows the physician to better manage the „neurogenic bladder.” If the bladder tends to be hyperactive with increased frequency of urination, medications (such as oxybutynin and tolterodine) can help to decrease frequency and urgency symptoms and improve bladder control. […] REM sleep behavioral disorder symptoms can be treated by melatonin, a natural hormone in the human body that is available over the counter. When melatonin is not effective, other therapies could be tried such as gabapentin or clonazepam. […] To improve obstructive sleep apnea, a machine that provides positive pressure ventilation with either a Continuous Positive Airway Pressure (CPAP) or Bilevel Positive Airway Pressure (BiPAP) system may be needed.

• #48 Multiple System Atrophy (MSA) | Movement Disorders Clinic

  https://www.movementdisordersclinic.com/multiple-system-atrophy-msa/

  Sleep problems such as REM sleep behavior disorder can be treated with medicines including clonazepam, melatonin, or some antidepressants. […] Some individuals with MSA may have significant difficulties with swallowing and may need a feeding tube or nutritional support. Speech therapy may be helpful in identifying strategies to address swallowing difficulties. […] Physical therapy helps maintain mobility, reduce contractures (chronic shortening of muscles or tendons around joints, which prevents the joints from moving freely), and decrease muscle spasms and abnormal posture. […] Individuals may eventually need assistive devices such as walkers and wheelchairs. Occupational therapists help with home safety and learning new ways to address activities of daily living such as dressing and eating.

• #49 Multiple System Atrophy: Essential Facts for Patients

  https://www.movementdisorders.org/MDS/Resources/Patient-Education/Multiple-System-Atrophy.htm

  For bladder and bowel problems, options include medications, regular toileting, bladder training, and catheterization. […] Drooling can be treated with medications and botulinum toxin injections into the saliva glands. […] Overall health may also benefit from physical therapy, occupational therapy, or speech and swallowing therapy.

• #50 Multiple System Atrophy

  https://neurosciences.ucsd.edu/centers-programs/movement-disorders/community/disease-overview/msa.html

  In at least one-third of patients, the parkinson’s type symptoms may improve with antiparkinsonian medications. The best treatment is carbidopa-levodopa or other formulations of levodopa. […] Physical therapy is also very important to prevent falls and maintain and improve gait. Our physical therapist helps determine the best walking aid when needed. A cane or a weighted walker with laser light may be very useful when there is freezing. Special programs like LSVT-BIG, an exercise treatment program for people with Parkinson’s disease, can significantly improve motor symptoms. […] Dystonia may improve with botulinum toxin injections, usually administered by the movement disorder specialist. Stridor may benefit from botulinum toxin injections, but at times is so severe that it may require a tracheostomy.

• #51 Multiple system atrophy – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/multiple-system-atrophy/diagnosis-treatment/drc-20356157

  Medicines to reduce Parkinson’s disease-like symptoms. Medicines that treat Parkinson’s disease, such as combined levodopa and carbidopa (Sinemet, Duopa, others), can help some people with MSA. The medicine can treat stiffness, trouble with balance and slow movements. Many people with multiple system atrophy do not respond to Parkinson’s medicines. The medicines also may become less effective after a few years. […] Medicines to treat erection problems. If you have trouble getting or keeping an erection, you can be treated with medicines such as sildenafil (Revatio, Viagra). This medicine helps manage erectile dysfunction but it can lower blood pressure. […] Steps to manage swallowing and breathing symptoms. If you have trouble swallowing, try eating softer foods. If swallowing or breathing symptoms become worse, you might need surgery to insert a feeding or breathing tube. A gastrostomy tube delivers food directly into your stomach. If you have sleep apnea, you might be treated with continuous positive airway pressure (CPAP) or bilevel positive airway pressure (BiPAP). Stridor also can be treated with CPAP.

• #52 Multiple system atrophy – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/multiple-system-atrophy/diagnosis-treatment/drc-20356157

  Bladder care. If you have trouble with bladder control, medicines can help in the earlier stages. But as MSA gets worse, you may need to have a soft tube inserted to drain your bladder. The soft tube is known as a catheter. […] Therapy. A physical therapist can help you maintain as much of your movement and strength as possible as the disease gets worse. A speech-language pathologist can help you improve or maintain your speech.

• #53 Multiple System Atrophy Treatment | University of Utah Health

  https://healthcare.utah.edu/neurosciences/neurology/movement-disorders/multiple-system-atrophy

  There is no cure for multiple system atrophy. MSA treatment focuses on managing symptoms. A multispecialty care team approach is best because MSA symptoms vary. […] Treatment needs will change as your MSA progresses. Palliative care can help both you and your caregivers. […] There are several types of therapy that can help you manage your MSA: […] Physical Therapy: It is important to work with a physical therapist. They will help you prevent falls and improve mobility. They will also teach you how to use a gait aid like a cane or walker if necessary. […] Occupational Therapy: An occupational therapist will teach you tips on how to manage daily activities like eating or bathing. […] Speech Therapy: Working with a speech therapist can help you with slurred speech or swallowing difficulties.

• #54 Multiple system atrophy – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/multiple-system-atrophy/diagnosis-treatment/drc-20356157

  Medicines to reduce Parkinson’s disease-like symptoms. Medicines that treat Parkinson’s disease, such as combined levodopa and carbidopa (Sinemet, Duopa, others), can help some people with MSA. The medicine can treat stiffness, trouble with balance and slow movements. Many people with multiple system atrophy do not respond to Parkinson’s medicines. The medicines also may become less effective after a few years. […] Medicines to treat erection problems. If you have trouble getting or keeping an erection, you can be treated with medicines such as sildenafil (Revatio, Viagra). This medicine helps manage erectile dysfunction but it can lower blood pressure. […] Steps to manage swallowing and breathing symptoms. If you have trouble swallowing, try eating softer foods. If swallowing or breathing symptoms become worse, you might need surgery to insert a feeding or breathing tube. A gastrostomy tube delivers food directly into your stomach. If you have sleep apnea, you might be treated with continuous positive airway pressure (CPAP) or bilevel positive airway pressure (BiPAP). Stridor also can be treated with CPAP.

• #55 Multiple System Atrophy (MSA): Symptoms, Diagnosis, Treatment

  https://www.webmd.com/brain/what-is-multiple-system-atrophy

  MSA has no cure. Treatment is aimed at managing the symptoms. […] The Parkinson’s drug levodopa can help manage shaking, stiffness, and slow movement. Stretching and exercise can keep your muscles strong and flexible. Physical, occupational, and speech therapists can help with walking and talking. […] To control your blood pressure, your doctor may prescribe you drugs like droxidopa, fludrocortisone, or midodrine. You could need a pacemaker to regulate your heart rate and increase your blood pressure. […] For bladder control, drugs including mirabegron, oxybutynin, tamsulosin, and tolterodine might help. You might use a catheter as well, which you can learn to use on your own. Catheters or medication can also help if you’re unable to empty your bladder. […] Softer foods can help with swallowing. You might need a breathing or feeding tube for more serious problems.

• #56 Multiple System Atrophy

  https://neurosciences.ucsd.edu/centers-programs/movement-disorders/community/disease-overview/msa.html

  Speech therapists assess the speech and swallowing functions. The LSVT-LOUD program for Parkinson’s disease can improve voice projection and speech quality. A modified barium swallowing test helps determine if patients can tolerate all types of consistencies of food. […] Occupational therapists help improve the patient’s performance of daily living activities, which promotes longer independence and better quality of life.

• #57 Multiple System Atrophy (MSA) – Brain Support Network

  https://www.brainsupportnetwork.org/education/multiple-system-atrophy/

  Multiple System Atrophy (MSA) treatments are few. All treatments are focused on symptoms. Parkinsonism may be treated by levodopa. (Some with MSA do have a response to this medication for a short period of time.) Orthostatic hypotension may be treated by a variety of medications. Urinary incontinence can be treated with medication, botox injections, catheters, or adult briefs. […] Therapy is worth trying: physical therapy, occupational therapy, and speech therapy. In our local support group, we have seen a few people with MSA benefit from two speech therapy programs designed for Parkinson’s Disease SPEAK OUT! (by the Parkinson Voice Project) and LSVT-LOUD (by LSVT). […] Movement disorder specialist Dr. Brent Bluett describes the symptomatic treatments possible for MSA that can improve quality of life. His messages: Each treatment individually may be minor, but in sum they can make a significant difference. And, there is always hope!

• #58 Multiple system atrophy – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/multiple-system-atrophy/diagnosis-treatment/drc-20356157

  Medicines to reduce Parkinson’s disease-like symptoms. Medicines that treat Parkinson’s disease, such as combined levodopa and carbidopa (Sinemet, Duopa, others), can help some people with MSA. The medicine can treat stiffness, trouble with balance and slow movements. Many people with multiple system atrophy do not respond to Parkinson’s medicines. The medicines also may become less effective after a few years. […] Medicines to treat erection problems. If you have trouble getting or keeping an erection, you can be treated with medicines such as sildenafil (Revatio, Viagra). This medicine helps manage erectile dysfunction but it can lower blood pressure. […] Steps to manage swallowing and breathing symptoms. If you have trouble swallowing, try eating softer foods. If swallowing or breathing symptoms become worse, you might need surgery to insert a feeding or breathing tube. A gastrostomy tube delivers food directly into your stomach. If you have sleep apnea, you might be treated with continuous positive airway pressure (CPAP) or bilevel positive airway pressure (BiPAP). Stridor also can be treated with CPAP.

• #59 Multiple System Atrophies (MSA)

  https://www.healthline.com/health/neurological-health/multiple-system-atrophy

  During the early stages of incontinence, your doctor may prescribe medications to help you control problems. During later stages, your doctor may recommend the insertion of a permanent catheter to allow you to pass urine comfortably. […] If youre experiencing difficulty swallowing, your doctor may recommend that you eat softer foods. If swallowing or breathing become difficult, your doctor may recommend surgically inserting a feeding or breathing tube to make these activities easier. In the later stages of MSA, your doctor may recommend a feeding tube that goes directly to your stomach. […] Through gentle exercise and repeated motion, physical therapy may help you maintain muscle strength and motor skills for as long as possible while MSA progresses. Speech-language therapy may also help you to maintain speech.

• #60

  https://link.springer.com/article/10.1007/s13311-020-00890-x

  Although historically thought to have limited cognitive impairment compared to other atypical syndromes and Parkinson disease, recent evidence indicates the presence of cognitive dysfunction and dementia estimated in 14 to 16% of MSA patients causing significant impact on quality of life. […] The management of orthostatic hypotension begins with behavioral or lifestyle changes including increased fluid and salt intake (i.e., volume expansion), wearing compression stockings or an abdominal binder, and being mindful of exacerbating conditions such as activity in hot, humid weather. […] Urinary dysfunction is the most common autonomic symptom of MSA and is recognized as a diagnostic criterion. […] Erectile dysfunction is a key criterion for diagnosis of probable MSA in men and, given the social stigma and patient embarrassment, is likely underreported.

• #61 Multiple system atrophy – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/multiple-system-atrophy/diagnosis-treatment/drc-20356157

  Medicines to reduce Parkinson’s disease-like symptoms. Medicines that treat Parkinson’s disease, such as combined levodopa and carbidopa (Sinemet, Duopa, others), can help some people with MSA. The medicine can treat stiffness, trouble with balance and slow movements. Many people with multiple system atrophy do not respond to Parkinson’s medicines. The medicines also may become less effective after a few years. […] Medicines to treat erection problems. If you have trouble getting or keeping an erection, you can be treated with medicines such as sildenafil (Revatio, Viagra). This medicine helps manage erectile dysfunction but it can lower blood pressure. […] Steps to manage swallowing and breathing symptoms. If you have trouble swallowing, try eating softer foods. If swallowing or breathing symptoms become worse, you might need surgery to insert a feeding or breathing tube. A gastrostomy tube delivers food directly into your stomach. If you have sleep apnea, you might be treated with continuous positive airway pressure (CPAP) or bilevel positive airway pressure (BiPAP). Stridor also can be treated with CPAP.

• #62 Multiple System Atrophy (MSA) – Neurologic Disorders – Merck Manual Professional Edition

  https://www.merckmanuals.com/professional/neurologic-disorders/autonomic-nervous-system/multiple-system-atrophy-msa

  If sweating is reduced or absent, patients are advised to avoid warm environments and overheating the body. Patients with dry mouth are advised to use good dental care and to have regular dental check-ups. Artificial tears may help patients with dry eyes. […] Many patients must self-catheterize their bladder. Sometimes medications that induce bladder contraction (eg, bethanechol) are used. […] A high-fiber diet and stool softeners can be used; for refractory cases, enemas may be necessary. […] Medications such as sildenafil or tadalafil can be used, but these medications may worsen orthostatic hypotension. […] Patients require supportive therapy because the disorder is progressive and fatal. Thus, clinicians should advise patients to prepare advance directives soon after multiples system atrophy is diagnosed.

• #63 Emerging Therapies For Multiple System Atrophy Treatment

  https://www.delveinsight.com/blog/multiple-system-atrophy-treatment

  Other drugs used to treat Parkinsons disease, in addition to levodopa, may be used to treat multiple system atrophy patients. These included dopamine agonists like ropinirole (Requip) and pramipexole (Mirapexin), which boost dopamine receptor activation in the brain. This aids the brains reception of dopamine messages. Midodrine hydrochloride (ProAmatine) has been used to treat low blood pressure, which has been linked to multiple system atrophy in certain cases. Low blood pressure can be treated using adrenergic medications such as ephedrine. Low blood pressure can also be treated with L-threo-dihydroxyphenylserine (L-DOPS or Lthreo-DOPS). […] Midodrine is thought to be more physiologic and well-tolerated than fludrocortisone, and other medicines worth testing include indomethacin and intranasal desmopressin. The breadth of treatment options for orthostatic hypotension in multiple system atrophy provides clinicians with some hope of alleviating the misery of many patients. Multiple system atrophy covers the major market with off-label and generic treatments. Clonazepam, vitamin E, propanolol, baclofen, or amantadine have demonstrated superior efficacy. However, in an open-label experiment with MSA-C patients, buspirone (off-label) improved upper-limb ataxia. Depending on the severity of the other symptoms, drugs such as sildenafil (Viagra), tadalafil (Cialis), or vardenafil (Levitra) may be used to treat urinary and erectile dysfunction (ED) symptoms that are common in males with multiple system atrophy.

• #64 Known Treatments – Defeat MSA New Zealand Trust

  https://defeatmsa.org.nz/what-is-msa/known-treatments/

  Non-pharmacologic treatment of sexual dysfunction include: Cognitive therapy to treat underlying depression and anxiety that is common among MSA patients. […] Medications used to treat sexual dysfunction include: PDE-5 inhibitors, including sildenafil, increase blood flow to the penis and have been proven to treat ED in patients with MSA. […] Non-pharmacologic treatment of REM behavior disorder include: Ensuring bedroom safety to prevent injury includes lowering the bed, padding bedside furniture and removing firearms is an important aspect to managing RBD. […] Medications used to help with REM behavior disorder include: Clonazepam, a benzodiazepine, has been shown to reduce frequency and severity and prevent injury in RBD. […] Non-pharmacologic treatment of psychiatric issues include: Cognitive therapy can not only help manage the mental health symptoms associated with MSA, it has also been shown to increase memory, help slow down cognitive decline, and decrease fall risk in patients with MSA.

• #65 Multiple System Atrophy Medication: Antiparkinson Agents, COMT Inhibitors, Antiparkinson Agents, Dopamine Agonists, Antiparkinson Agents, Anticholinergics, Urinary Antispasmodic Agents, Prokinetic Agents, Agents for Erectile Dysfunction, Corticosteroids,

  https://emedicine.medscape.com/article/1154583-medication

  As previously mentioned, pharmacologic therapy for multiple system atrophy (MSA) is directed mainly toward alleviation of symptoms of the movement disorder and orthostatic hypotension. Medications can also be used to treat urinary incontinence, constipation, erectile dysfunction, and supine hypertension. […] The movement-disorder component of MSA is usually treated with levodopa, dopaminergic agonists, anticholinergic agents, or amantadine, but results are rarely as favorable in MSA as in classic Parkinson disease. […] Many agents have been advocated for the management of orthostatic hypotension. […] In February 2014, droxidopa was approved by the FDA for the treatment of orthostatic hypotension. It is a synthetic amino precursor prodrug and is converted to norepinephrine. […] Water is a uniquely powerful pressor agent in the management of orthostatic hypotension in patients with MSA.

• #66 Multiple System Atrophy (MSA) – Neurologic Disorders – Merck Manual Professional Edition

  https://www.merckmanuals.com/professional/neurologic-disorders/autonomic-nervous-system/multiple-system-atrophy-msa

  If sweating is reduced or absent, patients are advised to avoid warm environments and overheating the body. Patients with dry mouth are advised to use good dental care and to have regular dental check-ups. Artificial tears may help patients with dry eyes. […] Many patients must self-catheterize their bladder. Sometimes medications that induce bladder contraction (eg, bethanechol) are used. […] A high-fiber diet and stool softeners can be used; for refractory cases, enemas may be necessary. […] Medications such as sildenafil or tadalafil can be used, but these medications may worsen orthostatic hypotension. […] Patients require supportive therapy because the disorder is progressive and fatal. Thus, clinicians should advise patients to prepare advance directives soon after multiples system atrophy is diagnosed.

• #67 Multiple System Atrophy – Causes, Symptoms and Treatment | Apollo Hospitals

  https://www.apollohospitals.com/diseases-and-conditions/multiple-system-atrophy-causes-symptoms-and-treatment

  Constipation can also be prevented with the help of a high-fiber diet. […] A focus is to identify the individuals at risk of developing the disease and finding the factors leading to MSA. As of now, an early diagnosis and treatment can slow down the progression of the disease and help increase the quality of your life. […] Unfortunately, there is no cure for multiple system atrophy. The treatment process is to slow down the progression of the disease.

• #68 Multiple system atrophy (MSA) | NHS inform

  https://www.nhsinform.scot/illnesses-and-conditions/brain-nerves-and-spinal-cord/multiple-system-atrophy-msa/

  Urology and continence specialists can recommend treatment to help manage bladder problems. […] If youre having problems emptying your bladder, you might have intermittent catheterisation. This involves putting a tube into the bladder to drain the pee. […] There are medications that can help manage this if it becomes disruptive during the night and affects your sleep. […] You should try to drink plenty fluids and eat a well balanced diet to try to avoid becoming constipated. […] If you do experience constipation youll be offered medication to take regularly. […] Theres medication available to help with erectile dysfunction but it can cause problems with your blood pressure. […] You might be offered a feeding tube if you experience coughing or choking when eating or drinking. […] You might be referred to a respiratory team if you have breathing problems like sleep apnoea or stridor.

• #69 Multiple System Atrophy (MSA) – Neurologic Disorders – Merck Manual Professional Edition

  https://www.merckmanuals.com/professional/neurologic-disorders/autonomic-nervous-system/multiple-system-atrophy-msa

  If sweating is reduced or absent, patients are advised to avoid warm environments and overheating the body. Patients with dry mouth are advised to use good dental care and to have regular dental check-ups. Artificial tears may help patients with dry eyes. […] Many patients must self-catheterize their bladder. Sometimes medications that induce bladder contraction (eg, bethanechol) are used. […] A high-fiber diet and stool softeners can be used; for refractory cases, enemas may be necessary. […] Medications such as sildenafil or tadalafil can be used, but these medications may worsen orthostatic hypotension. […] Patients require supportive therapy because the disorder is progressive and fatal. Thus, clinicians should advise patients to prepare advance directives soon after multiples system atrophy is diagnosed.

• #70 Multiple System Atrophy (MSA) – Brain, Spinal Cord, and Nerve Disorders – Merck Manual Consumer Version

  https://www.merckmanuals.com/home/brain-spinal-cord-and-nerve-disorders/autonomic-nervous-system-disorders/multiple-system-atrophy-msa

  A high-fiber diet and stool softeners are recommended. If constipation persists, enemas may be necessary. […] Usually, treatment consists of medications such as sildenafil, tadalafil, vardenafil, or avanafil, taken by mouth. However, these medications may make orthostatic hypotension worse. […] Physical, occupational, and speech therapists can teach people ways to compensate when walking, doing daily activities, and speaking become difficult. Specialists in palliative medicine focus on relieving pain and treating symptoms and helps people deal with end-of-life issues. Social workers can help people find support groups and, when symptoms become disabling, home health care or hospice services.

• #71 Multiple System Atrophy (MSA) – Brain, Spinal Cord, and Nerve Disorders – Merck Manual Consumer Version

  https://www.merckmanuals.com/home/brain-spinal-cord-and-nerve-disorders/autonomic-nervous-system-disorders/multiple-system-atrophy-msa

  A high-fiber diet and stool softeners are recommended. If constipation persists, enemas may be necessary. […] Usually, treatment consists of medications such as sildenafil, tadalafil, vardenafil, or avanafil, taken by mouth. However, these medications may make orthostatic hypotension worse. […] Physical, occupational, and speech therapists can teach people ways to compensate when walking, doing daily activities, and speaking become difficult. Specialists in palliative medicine focus on relieving pain and treating symptoms and helps people deal with end-of-life issues. Social workers can help people find support groups and, when symptoms become disabling, home health care or hospice services.

• #72 Current Management and Emerging Therapies in Multiple System Atrophy

  https://pmc.ncbi.nlm.nih.gov/articles/PMC7851250/

  To date there are no approved disease-modifying therapies for MSA; thus, treatment is focused mainly on symptom management tailored to the specific patient and importantly involves a multidisciplinary approach with rehab and other allied healthcare partners. […] Parkinsonism, dystonia, spasticity, dysarthria, dysphagia, autonomic failure, and sleep disorders are common symptoms that require tailored symptomatic management. […] While ideal, multidisciplinary care for MSA and other neurodegenerative disorders faces challenges in delivery. […] Current care models are often plagued by a lack of patient-centered care with poor continuity and delayed or reactive care delivery. […] The focus on synuclein has resulted in several trials targeting synuclein pathology through inhibition of aggregation, enhancement of degradation, or immunotherapy.

• #73 Known Treatments – Defeat MSA New Zealand Trust

  https://defeatmsa.org.nz/what-is-msa/known-treatments/

  Drugs used for Parkinsons disease may provide relief of motor symptoms for some MSA patients, though primarily in the earlier stages of the disease. […] Non-pharmacologic treatment of dystonia in MSA include: Speech therapy can be beneficial for patients whose dystonia affects their speech. […] Pharmacologic treatment of dystonia in MSA include: Botulinum toxin has been found to relieve many types of focal dystonias and is widely used in MSA. […] Non-pharmacologic treatment of cerebellar ataxia relies most on physical and occupational therapy. […] Non-pharmacologic treatments of neurogenic bladder include: Catheterization can help to control the symptoms of neurogenic bladder. […] Medications used to control neurogenic bladder include: Anticholinergic agents are used when post-void urine volume is 100ml.

• #74 Multiple System Atrophy (MSA) | Movement Disorders Clinic

  https://www.movementdisordersclinic.com/multiple-system-atrophy-msa/

  Currently, there are no treatments to delay the progressive neurodegeneration of MSA, and there is no cure. There are treatments to help people cope with the symptoms of MSA. […] In some individuals, levodopa may improve motor function; however, the benefit may not continue as the disease progresses. […] The fainting and lightheadedness from orthostatic hypotension may be treated with simple interventions such as wearing compression stockings, adding extra salt and/or water to the diet, and avoiding heavy meals. The drugs fludrocortisone and midodrine sometimes are prescribed. […] Bladder control problems are treated according to the nature of the problem. Anticholinergic drugs, such as oxybutynin or tolteridine, may help reduce the sudden urge to urinate. […] Fixed abnormal muscle postures (dystonia) may be controlled with injections of botulinum toxin.

• #75

  https://movementdisorders.ufhealth.org/for-patients/movement-disorder-information/multiple-system-atrophy-primer-many-faces-same-disease/

  Treatment of MSA remains largely supportive. About 30-60% of patients respond to typical Parkinsons medications such as carbidopa/levodopa (Sinemet), and dose trial of up to 1 gram/day of levodopa for a few months is recommended. Benefit seen early in disease often fades though, or becomes fraught with complications. […] More advanced motor symptoms, such as muscle spasm or fixed postures (dystonia), can be treated with muscle relaxants and sometimes by injection of botulinum toxin (i.e., Botox). […] Physical and occupational therapies for gait and balance, range of motion and mobility, and help with activities of daily living are critical and require staff familiar with Parkinsonian patient needs. […] Treatment initially begins with conservative therapies including increased fluid intake, salt in diet (considering of course any concomitant heart disease), and wearing pressure stockings or binder. If these are not enough, drug treatment may be necessary. Options include blood volume increasers (fludrocortisone) or pressor agents (e.g., midodrine). Both increase BP thereby reducing episodes of low BP, but the later can also cause excessive high BP usually when lying down. Careful monitoring of BP is needed, avoiding ups and downs, and a happy medium found for each individual. Urinary and bowel symptoms likewise can be treated with select agents depending on the issue. Sleep disturbance can also be successfully treated depending on cause.

• #76 Known Treatments – Defeat MSA New Zealand Trust

  https://defeatmsa.org.nz/what-is-msa/known-treatments/

  Drugs used for Parkinsons disease may provide relief of motor symptoms for some MSA patients, though primarily in the earlier stages of the disease. […] Non-pharmacologic treatment of dystonia in MSA include: Speech therapy can be beneficial for patients whose dystonia affects their speech. […] Pharmacologic treatment of dystonia in MSA include: Botulinum toxin has been found to relieve many types of focal dystonias and is widely used in MSA. […] Non-pharmacologic treatment of cerebellar ataxia relies most on physical and occupational therapy. […] Non-pharmacologic treatments of neurogenic bladder include: Catheterization can help to control the symptoms of neurogenic bladder. […] Medications used to control neurogenic bladder include: Anticholinergic agents are used when post-void urine volume is 100ml.

• #77

  https://link.springer.com/article/10.1007/s13311-020-00890-x

  Deep brain stimulation for parkinsonism in MSA is not recommended as symptoms often poorly respond and rapidly progress relative to Parkinson disease. […] Medical therapies for dystonia including benzodiazepines and anticholinergics are not commonly used because of cognitive and respiratory risks. […] There are currently no medications available that provide evidence-supported improvement in ataxic symptoms in MSA. […] Sleep disorders are common in MSA and include insomnia, daytime somnolence, restless legs syndrome (RLS), REM sleep behavior disorder (RBD), and sleep disordered breathing. […] Despite the frequency and severity of depression and anxiety in patients with MSA with up to half of patients reporting symptoms and evidence they play a major role in quality of life, randomized controlled trials providing therapeutic guidance are lacking.

• #78 Known Treatments – Defeat MSA New Zealand Trust

  https://defeatmsa.org.nz/what-is-msa/known-treatments/

  Medications used to help with psychiatric issues include: Selective serotonin reuptake inhibitors are effective anti-depressants and may have a lower risk of orthostatic hypotension than other drugs to treat depression. […] Non-Pharmaceutical treatment of breathing problems: The primary treatment of sleep apnea is the use of continuous positive airway pressure (CPAP) for patients with mild to moderate stridor and can be useful for symptomatic control. […] Medications for the treatment of breathing problems: Botulinum toxin injected into the vocal cords has been studied as a treatment of stridor in MSA patients, but there is not enough evidence to be recommended. […] Non-pharmacologic treatment for pain include: Exercise and physical therapy are ways to help deal with the pain associated with MSA. […] Medication for the treatment of pain include: Dopaminergic medication, including levodopa and pramipexole, have shown promise for pain relief. […] Dietary modifications have been shown to provide neuroprotective effects and may hold promise for patients with MSA.

• #79 Known Treatments – Defeat MSA New Zealand Trust

  https://defeatmsa.org.nz/what-is-msa/known-treatments/

  Non-pharmacologic treatment of sexual dysfunction include: Cognitive therapy to treat underlying depression and anxiety that is common among MSA patients. […] Medications used to treat sexual dysfunction include: PDE-5 inhibitors, including sildenafil, increase blood flow to the penis and have been proven to treat ED in patients with MSA. […] Non-pharmacologic treatment of REM behavior disorder include: Ensuring bedroom safety to prevent injury includes lowering the bed, padding bedside furniture and removing firearms is an important aspect to managing RBD. […] Medications used to help with REM behavior disorder include: Clonazepam, a benzodiazepine, has been shown to reduce frequency and severity and prevent injury in RBD. […] Non-pharmacologic treatment of psychiatric issues include: Cognitive therapy can not only help manage the mental health symptoms associated with MSA, it has also been shown to increase memory, help slow down cognitive decline, and decrease fall risk in patients with MSA.

• #80 Multiple System Atrophy: Advances in Diagnosis and Therapy

  https://www.e-jmd.org/journal/view.php?number=416

  Autologous MSCs are expected to modulate neuroinflammation, inhibit cell death and intercellular transmission, promote neurogenesis and autophagy, degrade -synuclein aggregates, stabilize axonal transport and phagocytose -synuclein by microglia. […] Other treatments, such as the mammalian target of rapamycin inhibitor sirolimus, which induces autophagy, were ineffective after 48 weeks of treatment. […] Another retrospective natural history study revealed that patients with MSA treated with SSRIs showed a better prognosis than untreated patients. […] Further studies are needed to determine whether serotonin-targeted therapy alleviates several symptoms and modifies the disease course of MSA.

• #81 Current Management and Emerging Therapies in Multiple System Atrophy

  https://pmc.ncbi.nlm.nih.gov/articles/PMC7851250/

  To date there are no approved disease-modifying therapies for MSA; thus, treatment is focused mainly on symptom management tailored to the specific patient and importantly involves a multidisciplinary approach with rehab and other allied healthcare partners. […] Parkinsonism, dystonia, spasticity, dysarthria, dysphagia, autonomic failure, and sleep disorders are common symptoms that require tailored symptomatic management. […] While ideal, multidisciplinary care for MSA and other neurodegenerative disorders faces challenges in delivery. […] Current care models are often plagued by a lack of patient-centered care with poor continuity and delayed or reactive care delivery. […] The focus on synuclein has resulted in several trials targeting synuclein pathology through inhibition of aggregation, enhancement of degradation, or immunotherapy.

• #82

  https://link.springer.com/article/10.1007/s13311-020-00890-x

  To date there are no approved disease-modifying therapies for MSA; thus, treatment is focused mainly on symptom management tailored to the specific patient and importantly involves a multidisciplinary approach with rehab and other allied healthcare partners. […] While ideal, multidisciplinary care for MSA and other neurodegenerative disorders faces challenges in delivery. […] Nearly a third of MSA-P patients benefit from levodopa therapy, but temporarily with mean duration of 3.5 years in one study. […] Dopamine agonists may be used as a second choice, but lack supporting evidence and are generally not preferred because of their increased side effect profile relative to levodopa. […] Nonpharmacological approaches such as physical, occupational, and speech therapy are both complementary and essential therapies in MSA.

• #83 Multiple system atrophy – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/multiple-system-atrophy/diagnosis-treatment/drc-20356157

  Bladder care. If you have trouble with bladder control, medicines can help in the earlier stages. But as MSA gets worse, you may need to have a soft tube inserted to drain your bladder. The soft tube is known as a catheter. […] Therapy. A physical therapist can help you maintain as much of your movement and strength as possible as the disease gets worse. A speech-language pathologist can help you improve or maintain your speech.

• #84 Physical Therapy for Managing Multiple System Atrophy – Tandem Strength & Balance

  https://www.tandemsb.com/physical-therapy-for-managing-multiple-system-atrophy/

  Multiple System Atrophy (MSA) is a rare neurodegenerative disorder that affects the autonomic nervous system and can cause significant motor and muscle impairments. […] One way to manage these symptoms and maintain motor and muscle capacity is through physical therapy. This specialized therapy focuses on improving movement, function, and overall quality of life for individuals with MSA. […] Physical therapy can be an effective mode of treatment for individuals with MSA. It aims to improve mobility, strength, and balance and helps prevent complications such as muscle contractures, bedsores, and pneumonia. […] By working closely with a physical therapist, individuals with MSA can learn exercises and techniques that help maintain their motor and muscle capacity. […] The main goal of physical therapy in MSA is to improve and maintain an individuals ability to move, perform daily tasks, and reduce the risk of falls.

• #85 Non-Drug Therapies – Mission MSA

  https://missionmsa.org/non-drug-therapies/

  Multiple System Atrophy (MSA) is a rare neurological disorder characterized by a combination of symptoms that affect movement, autonomic function, and other body functions. While there is currently no cure for MSA, various non-drug therapies can help manage symptoms and improve quality of life. Its essential for individuals with MSA to work closely with a multidisciplinary healthcare team to develop a comprehensive treatment plan tailored to their specific needs and symptoms. […] Here’s a list of some non-drug therapies commonly used in the management of MSA: Physical therapy aims to improve mobility, balance, and muscle strength. Exercises tailored to the individuals needs can help manage symptoms such as gait difficulties and muscle stiffness. Occupational therapy focuses on assisting individuals in performing daily activities more independently despite physical limitations. It may involve adaptations to the home environment and the use of assistive devices. Speech therapy can be beneficial for individuals with MSA who experience speech and swallowing difficulties. Speech therapists can provide exercises and techniques to improve communication, swallowing function, and reduce the risk of aspiration. Various mobility aids such as canes, walkers, and wheelchairs can help individuals with MSA maintain mobility and independence. There are numerous assistive devices available to help with activities of daily living, such as dressing aids, adaptive utensils, and devices to assist with writing or typing. As respiratory function can be affected in later stages of MSA, respiratory therapy may be recommended to help manage breathing difficulties and improve respiratory function. Coping with a chronic and progressive condition like MSA can be challenging. Psychotherapy and counseling can provide emotional support, coping strategies, and assistance in managing depression or anxiety that may arise. A registered dietitian can provide guidance on maintaining a balanced diet and managing swallowing difficulties to ensure adequate nutrition and hydration. Strategies to manage orthostatic hypotension, such as increasing salt intake, wearing compression stockings, or sleeping with the head in an elevated position may be recommended. Techniques such as yoga, tai chi, and mindfulness meditation may help manage stress, improve relaxation, and enhance overall well-being.

• #86 Multiple System Atrophy (MSA) | Movement Disorders Clinic

  https://www.movementdisordersclinic.com/multiple-system-atrophy-msa/

  Sleep problems such as REM sleep behavior disorder can be treated with medicines including clonazepam, melatonin, or some antidepressants. […] Some individuals with MSA may have significant difficulties with swallowing and may need a feeding tube or nutritional support. Speech therapy may be helpful in identifying strategies to address swallowing difficulties. […] Physical therapy helps maintain mobility, reduce contractures (chronic shortening of muscles or tendons around joints, which prevents the joints from moving freely), and decrease muscle spasms and abnormal posture. […] Individuals may eventually need assistive devices such as walkers and wheelchairs. Occupational therapists help with home safety and learning new ways to address activities of daily living such as dressing and eating.

• #87 Multiple System Atrophy

  https://neurosciences.ucsd.edu/centers-programs/movement-disorders/community/disease-overview/msa.html

  In at least one-third of patients, the parkinson’s type symptoms may improve with antiparkinsonian medications. The best treatment is carbidopa-levodopa or other formulations of levodopa. […] Physical therapy is also very important to prevent falls and maintain and improve gait. Our physical therapist helps determine the best walking aid when needed. A cane or a weighted walker with laser light may be very useful when there is freezing. Special programs like LSVT-BIG, an exercise treatment program for people with Parkinson’s disease, can significantly improve motor symptoms. […] Dystonia may improve with botulinum toxin injections, usually administered by the movement disorder specialist. Stridor may benefit from botulinum toxin injections, but at times is so severe that it may require a tracheostomy.

• #88 Non-Drug Therapies – Mission MSA

  https://missionmsa.org/non-drug-therapies/

  Multiple System Atrophy (MSA) is a rare neurological disorder characterized by a combination of symptoms that affect movement, autonomic function, and other body functions. While there is currently no cure for MSA, various non-drug therapies can help manage symptoms and improve quality of life. Its essential for individuals with MSA to work closely with a multidisciplinary healthcare team to develop a comprehensive treatment plan tailored to their specific needs and symptoms. […] Here’s a list of some non-drug therapies commonly used in the management of MSA: Physical therapy aims to improve mobility, balance, and muscle strength. Exercises tailored to the individuals needs can help manage symptoms such as gait difficulties and muscle stiffness. Occupational therapy focuses on assisting individuals in performing daily activities more independently despite physical limitations. It may involve adaptations to the home environment and the use of assistive devices. Speech therapy can be beneficial for individuals with MSA who experience speech and swallowing difficulties. Speech therapists can provide exercises and techniques to improve communication, swallowing function, and reduce the risk of aspiration. Various mobility aids such as canes, walkers, and wheelchairs can help individuals with MSA maintain mobility and independence. There are numerous assistive devices available to help with activities of daily living, such as dressing aids, adaptive utensils, and devices to assist with writing or typing. As respiratory function can be affected in later stages of MSA, respiratory therapy may be recommended to help manage breathing difficulties and improve respiratory function. Coping with a chronic and progressive condition like MSA can be challenging. Psychotherapy and counseling can provide emotional support, coping strategies, and assistance in managing depression or anxiety that may arise. A registered dietitian can provide guidance on maintaining a balanced diet and managing swallowing difficulties to ensure adequate nutrition and hydration. Strategies to manage orthostatic hypotension, such as increasing salt intake, wearing compression stockings, or sleeping with the head in an elevated position may be recommended. Techniques such as yoga, tai chi, and mindfulness meditation may help manage stress, improve relaxation, and enhance overall well-being.

• #89 Multiple System Atrophy / MSA | ColumbiaDoctors

  https://www.columbiadoctors.org/treatments-conditions/multiple-system-atrophy-msa

  Levodopa is a medication used to improve motor function, though it may become less effective over time. […] Occupational therapists advise parents about home safety and new ways to address routine activities like dressing and eating. […] Physical therapy may be prescribed to maintain mobility, reduce contractures (chronic shortening of muscles or tendons around joints), decrease muscle spasms, and address abnormal posture. […] Rigid postures (dystonia) may be helped by injections of botulinum toxin. […] Sleep problems are treated with medicines such as clonazepam, melatonin, or some antidepressants.

• #90 Multiple system atrophy | Monash Health

  https://monashhealth.org/services/movement-disorders-program/understanding-movement-disorders/multiple-system-atrophy/

  There are currently no medications that can reverse or slow down the cognitive changes that occur with MSA. […] A physiotherapist specialised in movement disorders such as MSA can assess walking and balance problems and recommend ways to improve mobility and safety. […] An occupational therapist specialised in movement disorders such as MSA can assess the person at home and suggest ways to improve safety, both inside and outside the home. […] A speech pathologist specialised in movement disorders such as MSA can assess speech and swallowing difficulties and teach strategies to improve them. […] A dietitian specialised in movement disorders such as MSA can assess the persons diet and provide them with suggested menus to improve any dietary problems they may have. […] A social worker specialised in movement disorders such as MSA can assist the person with MSA, their caregiver and family negotiate the challenges faced across the life time of the persons condition.

• #91 Non-Drug Therapies – Mission MSA

  https://missionmsa.org/non-drug-therapies/

  Multiple System Atrophy (MSA) is a rare neurological disorder characterized by a combination of symptoms that affect movement, autonomic function, and other body functions. While there is currently no cure for MSA, various non-drug therapies can help manage symptoms and improve quality of life. Its essential for individuals with MSA to work closely with a multidisciplinary healthcare team to develop a comprehensive treatment plan tailored to their specific needs and symptoms. […] Here’s a list of some non-drug therapies commonly used in the management of MSA: Physical therapy aims to improve mobility, balance, and muscle strength. Exercises tailored to the individuals needs can help manage symptoms such as gait difficulties and muscle stiffness. Occupational therapy focuses on assisting individuals in performing daily activities more independently despite physical limitations. It may involve adaptations to the home environment and the use of assistive devices. Speech therapy can be beneficial for individuals with MSA who experience speech and swallowing difficulties. Speech therapists can provide exercises and techniques to improve communication, swallowing function, and reduce the risk of aspiration. Various mobility aids such as canes, walkers, and wheelchairs can help individuals with MSA maintain mobility and independence. There are numerous assistive devices available to help with activities of daily living, such as dressing aids, adaptive utensils, and devices to assist with writing or typing. As respiratory function can be affected in later stages of MSA, respiratory therapy may be recommended to help manage breathing difficulties and improve respiratory function. Coping with a chronic and progressive condition like MSA can be challenging. Psychotherapy and counseling can provide emotional support, coping strategies, and assistance in managing depression or anxiety that may arise. A registered dietitian can provide guidance on maintaining a balanced diet and managing swallowing difficulties to ensure adequate nutrition and hydration. Strategies to manage orthostatic hypotension, such as increasing salt intake, wearing compression stockings, or sleeping with the head in an elevated position may be recommended. Techniques such as yoga, tai chi, and mindfulness meditation may help manage stress, improve relaxation, and enhance overall well-being.

• #92 Non-Drug Therapies – Mission MSA

  https://missionmsa.org/non-drug-therapies/

  Multiple System Atrophy (MSA) is a rare neurological disorder characterized by a combination of symptoms that affect movement, autonomic function, and other body functions. While there is currently no cure for MSA, various non-drug therapies can help manage symptoms and improve quality of life. Its essential for individuals with MSA to work closely with a multidisciplinary healthcare team to develop a comprehensive treatment plan tailored to their specific needs and symptoms. […] Here’s a list of some non-drug therapies commonly used in the management of MSA: Physical therapy aims to improve mobility, balance, and muscle strength. Exercises tailored to the individuals needs can help manage symptoms such as gait difficulties and muscle stiffness. Occupational therapy focuses on assisting individuals in performing daily activities more independently despite physical limitations. It may involve adaptations to the home environment and the use of assistive devices. Speech therapy can be beneficial for individuals with MSA who experience speech and swallowing difficulties. Speech therapists can provide exercises and techniques to improve communication, swallowing function, and reduce the risk of aspiration. Various mobility aids such as canes, walkers, and wheelchairs can help individuals with MSA maintain mobility and independence. There are numerous assistive devices available to help with activities of daily living, such as dressing aids, adaptive utensils, and devices to assist with writing or typing. As respiratory function can be affected in later stages of MSA, respiratory therapy may be recommended to help manage breathing difficulties and improve respiratory function. Coping with a chronic and progressive condition like MSA can be challenging. Psychotherapy and counseling can provide emotional support, coping strategies, and assistance in managing depression or anxiety that may arise. A registered dietitian can provide guidance on maintaining a balanced diet and managing swallowing difficulties to ensure adequate nutrition and hydration. Strategies to manage orthostatic hypotension, such as increasing salt intake, wearing compression stockings, or sleeping with the head in an elevated position may be recommended. Techniques such as yoga, tai chi, and mindfulness meditation may help manage stress, improve relaxation, and enhance overall well-being.

• #93 Multiple system atrophy | Monash Health

  https://monashhealth.org/services/movement-disorders-program/understanding-movement-disorders/multiple-system-atrophy/

  There are currently no medications that can reverse or slow down the cognitive changes that occur with MSA. […] A physiotherapist specialised in movement disorders such as MSA can assess walking and balance problems and recommend ways to improve mobility and safety. […] An occupational therapist specialised in movement disorders such as MSA can assess the person at home and suggest ways to improve safety, both inside and outside the home. […] A speech pathologist specialised in movement disorders such as MSA can assess speech and swallowing difficulties and teach strategies to improve them. […] A dietitian specialised in movement disorders such as MSA can assess the persons diet and provide them with suggested menus to improve any dietary problems they may have. […] A social worker specialised in movement disorders such as MSA can assist the person with MSA, their caregiver and family negotiate the challenges faced across the life time of the persons condition.

• #94 Non-Drug Therapies – Mission MSA

  https://missionmsa.org/non-drug-therapies/

  Multiple System Atrophy (MSA) is a rare neurological disorder characterized by a combination of symptoms that affect movement, autonomic function, and other body functions. While there is currently no cure for MSA, various non-drug therapies can help manage symptoms and improve quality of life. Its essential for individuals with MSA to work closely with a multidisciplinary healthcare team to develop a comprehensive treatment plan tailored to their specific needs and symptoms. […] Here’s a list of some non-drug therapies commonly used in the management of MSA: Physical therapy aims to improve mobility, balance, and muscle strength. Exercises tailored to the individuals needs can help manage symptoms such as gait difficulties and muscle stiffness. Occupational therapy focuses on assisting individuals in performing daily activities more independently despite physical limitations. It may involve adaptations to the home environment and the use of assistive devices. Speech therapy can be beneficial for individuals with MSA who experience speech and swallowing difficulties. Speech therapists can provide exercises and techniques to improve communication, swallowing function, and reduce the risk of aspiration. Various mobility aids such as canes, walkers, and wheelchairs can help individuals with MSA maintain mobility and independence. There are numerous assistive devices available to help with activities of daily living, such as dressing aids, adaptive utensils, and devices to assist with writing or typing. As respiratory function can be affected in later stages of MSA, respiratory therapy may be recommended to help manage breathing difficulties and improve respiratory function. Coping with a chronic and progressive condition like MSA can be challenging. Psychotherapy and counseling can provide emotional support, coping strategies, and assistance in managing depression or anxiety that may arise. A registered dietitian can provide guidance on maintaining a balanced diet and managing swallowing difficulties to ensure adequate nutrition and hydration. Strategies to manage orthostatic hypotension, such as increasing salt intake, wearing compression stockings, or sleeping with the head in an elevated position may be recommended. Techniques such as yoga, tai chi, and mindfulness meditation may help manage stress, improve relaxation, and enhance overall well-being.

• #95 Non-Drug Therapies – Mission MSA

  https://missionmsa.org/non-drug-therapies/

  Multiple System Atrophy (MSA) is a rare neurological disorder characterized by a combination of symptoms that affect movement, autonomic function, and other body functions. While there is currently no cure for MSA, various non-drug therapies can help manage symptoms and improve quality of life. Its essential for individuals with MSA to work closely with a multidisciplinary healthcare team to develop a comprehensive treatment plan tailored to their specific needs and symptoms. […] Here’s a list of some non-drug therapies commonly used in the management of MSA: Physical therapy aims to improve mobility, balance, and muscle strength. Exercises tailored to the individuals needs can help manage symptoms such as gait difficulties and muscle stiffness. Occupational therapy focuses on assisting individuals in performing daily activities more independently despite physical limitations. It may involve adaptations to the home environment and the use of assistive devices. Speech therapy can be beneficial for individuals with MSA who experience speech and swallowing difficulties. Speech therapists can provide exercises and techniques to improve communication, swallowing function, and reduce the risk of aspiration. Various mobility aids such as canes, walkers, and wheelchairs can help individuals with MSA maintain mobility and independence. There are numerous assistive devices available to help with activities of daily living, such as dressing aids, adaptive utensils, and devices to assist with writing or typing. As respiratory function can be affected in later stages of MSA, respiratory therapy may be recommended to help manage breathing difficulties and improve respiratory function. Coping with a chronic and progressive condition like MSA can be challenging. Psychotherapy and counseling can provide emotional support, coping strategies, and assistance in managing depression or anxiety that may arise. A registered dietitian can provide guidance on maintaining a balanced diet and managing swallowing difficulties to ensure adequate nutrition and hydration. Strategies to manage orthostatic hypotension, such as increasing salt intake, wearing compression stockings, or sleeping with the head in an elevated position may be recommended. Techniques such as yoga, tai chi, and mindfulness meditation may help manage stress, improve relaxation, and enhance overall well-being.

• #96 Multiple System Atrophy

  https://neurosciences.ucsd.edu/centers-programs/movement-disorders/community/disease-overview/msa.html

  In at least one-third of patients, the parkinson’s type symptoms may improve with antiparkinsonian medications. The best treatment is carbidopa-levodopa or other formulations of levodopa. […] Physical therapy is also very important to prevent falls and maintain and improve gait. Our physical therapist helps determine the best walking aid when needed. A cane or a weighted walker with laser light may be very useful when there is freezing. Special programs like LSVT-BIG, an exercise treatment program for people with Parkinson’s disease, can significantly improve motor symptoms. […] Dystonia may improve with botulinum toxin injections, usually administered by the movement disorder specialist. Stridor may benefit from botulinum toxin injections, but at times is so severe that it may require a tracheostomy.

• #97 Current Management and Emerging Therapies in Multiple System Atrophy

  https://pmc.ncbi.nlm.nih.gov/articles/PMC7851250/

  Despite promising preclinical data and ongoing clinical trials in this area, caution is warranted given previous failed trials of drugs claiming a similar ability to affect -synuclein aggregation. […] A relatively limited number of trials to date have failed to identify an effective disease-modifying therapy.

• #98

  https://link.springer.com/article/10.1007/s00415-024-12269-5

  Current treatment focuses primarily on symptomatic management. […] Over the past two decades, the number of clinical trials to modify MSA has increased. Unfortunately, most attempts have failed, possibly due to incomplete understanding of pathophysiology, inadequacies in preclinical animal models, and lack of early and accurate diagnosis of the disease. […] The most straightforward therapeutic target and treatment strategy is directed against pathological oligomer -synuclein. Other strategies aim to enhance the synaptic function, restore the proteostasis, inhibit neuroinflammation and provide neuroprotection for neuronal death. […] Treatment strategies targeting -synuclein have been widely adopted and evaluated in clinical trials. These include immunotherapy, inhibition of -synuclein aggregation, and -synuclein gene therapy by antisense oligonucleotides (ASO).

• #99

  https://link.springer.com/article/10.1007/s00415-024-12269-5

  Current treatment focuses primarily on symptomatic management. […] Over the past two decades, the number of clinical trials to modify MSA has increased. Unfortunately, most attempts have failed, possibly due to incomplete understanding of pathophysiology, inadequacies in preclinical animal models, and lack of early and accurate diagnosis of the disease. […] The most straightforward therapeutic target and treatment strategy is directed against pathological oligomer -synuclein. Other strategies aim to enhance the synaptic function, restore the proteostasis, inhibit neuroinflammation and provide neuroprotection for neuronal death. […] Treatment strategies targeting -synuclein have been widely adopted and evaluated in clinical trials. These include immunotherapy, inhibition of -synuclein aggregation, and -synuclein gene therapy by antisense oligonucleotides (ASO).

• #100 Next Era of Multiple System Atrophy Treatment

  https://www.delveinsight.com/blog/future-of-multiple-system-atrophy-treatment

  Alpha-synuclein, a protein primarily found in presynaptic terminals, has emerged as a pivotal target in the search for disease-modifying treatments (DMTs) for MSA. […] Recent research has shown that alpha-synuclein oligomers, rather than large fibrillar aggregates, are the primary neurotoxic species, driving neuronal dysfunction and damage. […] These findings highlight the potential of targeting alpha-synuclein as a key therapeutic pathway, offering hope for novel treatments that could modify the disease course in MSA patients and alleviate their symptoms. […] Amlenetug (Lu AF82422), the anticipated first disease-modifying treatment (DMT) for MSA according to the Lundbeck’s latest reports, is a monoclonal antibody targeting alpha-synuclein. […] The encouraging findings from the Phase II trial showed a 19% reduction in clinical progression (measured by the UMSARS total score), but the results were not statistically significant.

• #101 Next Era of Multiple System Atrophy Treatment

  https://www.delveinsight.com/blog/future-of-multiple-system-atrophy-treatment

  Alpha-synuclein, a protein primarily found in presynaptic terminals, has emerged as a pivotal target in the search for disease-modifying treatments (DMTs) for MSA. […] Recent research has shown that alpha-synuclein oligomers, rather than large fibrillar aggregates, are the primary neurotoxic species, driving neuronal dysfunction and damage. […] These findings highlight the potential of targeting alpha-synuclein as a key therapeutic pathway, offering hope for novel treatments that could modify the disease course in MSA patients and alleviate their symptoms. […] Amlenetug (Lu AF82422), the anticipated first disease-modifying treatment (DMT) for MSA according to the Lundbeck’s latest reports, is a monoclonal antibody targeting alpha-synuclein. […] The encouraging findings from the Phase II trial showed a 19% reduction in clinical progression (measured by the UMSARS total score), but the results were not statistically significant.

• #102 Emerging Therapies For Multiple System Atrophy Treatment

  https://www.delveinsight.com/blog/multiple-system-atrophy-treatment

  Considering all the existing knowledge gaps and the void of effective neuroprotective treatment, some major pharma players are proactive with their early and mid-phase trial candidates in the pursuit of a breakthrough therapy to dominate the multiple system atrophy treatment market. H Lundbeck A/S (Lu AF82422), Theravance Biopharma (Ampreloxetine) (TD-9855), Brain Neurotherapy Bio, Inc (AAV2-GDNF gene therapy), Ionis Pharmaceuticals, Inc. (ION464), Alterity Therapeutics (ATH434), Enterin Inc (ENT-01) and others are the leading companies working in the segment with their lead assets in different multiple system atrophy clinical trials. […] The human Monoclonal Antibody (mAb) Lu AF82422 targets the toxic alpha-synuclein protein, which is a pathogenic characteristic of multiple spinal atrophy. To eliminate these toxic proteins, the chemical operates similarly to the bodys natural immune system. Lu AF82422 may potentially reduce or stop the progression of MSA because it tackles the diseases underlying biology, according to Lundbeck. The EMA granted Lu AF82422 ODD in April 2021, and the AMULET project has been approved by the FDA and is ready to recruit the first patient.

• #103 Multiple System Atrophy Research Program | NYU Langone Health

  https://med.nyu.edu/departments-institutes/neurology/research/divisions-centers/autonomic-disorders/multiple-system-atrophy-research-program

  We continue to have a number of clinical trial opportunities that are open to patients with MSA according to their specific needs. […] We are currently testing ampreloxetine, a new drug for orthostatic hypotension specifically designed for people with MSA. […] We are also conducting studies to test possible disease modifying treatments by using antibodies to remove abnormal alpha-synuclein, a protein thought to mediate disease progression in MSA and Parkinsons disease. This may be done by injecting the antibodies (TAK-341 and AMULET studies for MSA), or by using a vaccine to help the body produce these antibodies (UB-312 for MSA and Parkinsons disease).

• #104 Multiple System Atrophy Research Program | NYU Langone Health

  https://med.nyu.edu/departments-institutes/neurology/research/divisions-centers/autonomic-disorders/multiple-system-atrophy-research-program

  We continue to have a number of clinical trial opportunities that are open to patients with MSA according to their specific needs. […] We are currently testing ampreloxetine, a new drug for orthostatic hypotension specifically designed for people with MSA. […] We are also conducting studies to test possible disease modifying treatments by using antibodies to remove abnormal alpha-synuclein, a protein thought to mediate disease progression in MSA and Parkinsons disease. This may be done by injecting the antibodies (TAK-341 and AMULET studies for MSA), or by using a vaccine to help the body produce these antibodies (UB-312 for MSA and Parkinsons disease).

• #105 Emerging Therapies For Multiple System Atrophy Treatment

  https://www.delveinsight.com/blog/multiple-system-atrophy-treatment

  Considering all the existing knowledge gaps and the void of effective neuroprotective treatment, some major pharma players are proactive with their early and mid-phase trial candidates in the pursuit of a breakthrough therapy to dominate the multiple system atrophy treatment market. H Lundbeck A/S (Lu AF82422), Theravance Biopharma (Ampreloxetine) (TD-9855), Brain Neurotherapy Bio, Inc (AAV2-GDNF gene therapy), Ionis Pharmaceuticals, Inc. (ION464), Alterity Therapeutics (ATH434), Enterin Inc (ENT-01) and others are the leading companies working in the segment with their lead assets in different multiple system atrophy clinical trials. […] The human Monoclonal Antibody (mAb) Lu AF82422 targets the toxic alpha-synuclein protein, which is a pathogenic characteristic of multiple spinal atrophy. To eliminate these toxic proteins, the chemical operates similarly to the bodys natural immune system. Lu AF82422 may potentially reduce or stop the progression of MSA because it tackles the diseases underlying biology, according to Lundbeck. The EMA granted Lu AF82422 ODD in April 2021, and the AMULET project has been approved by the FDA and is ready to recruit the first patient.

• #106

  https://link.springer.com/article/10.1007/s00415-024-12269-5

  In recent years, increasing evidence has supported the theory that -synuclein is primarily produced by the neurons, where it aggregates and spreads into oligodendrocytes via the extracellular environment, as mentioned earlier. This provided a clear rationale for targeting the -synuclein-mediated extracellular pathology through immunotherapeutic approaches. […] The development outlined above suggests that ASO is likely to become a significant new therapeutic category for neurodegenerative diseases and rare diseases. […] Given that intracellular aggregation of -synuclein plays a critical role in the MSA pathology, reducing the -synuclein protein production using ASO targeting SNCA gene is a straightforward and promising mechanism of action, although current research in this area remains at an early stage.

• #107 Emerging Therapies For Multiple System Atrophy Treatment

  https://www.delveinsight.com/blog/multiple-system-atrophy-treatment

  ENT-01 is an oral lab-made drug produced from squalamine, a substance identified in the liver and gall bladder of the dogfish shark. Preclinical studies suggest ENT-01s efficacy in removing harmful alpha-synuclein aggregates and preventing their development within gut nerve cells, hence boosting cells normal signaling. Recently on 24 May 2023, Enterin Inc. announced the FDAs acceptance of an investigator-sponsored Investigational New Drug (IND) application (166532) to treat a patient with prodromal multisystem atrophy (MSA) with ENT-01. Treatment will be continued continuously or until substantial adverse effects occur that necessitate drug withdrawal. […] Alteritys lead candidate, ATH434, is the first of a new generation of small molecules designed to block the aggregation of pathogenic proteins implicated in neurodegeneration. ATH434 decreases the aberrant accumulation of S and tau proteins in animal illness models by restoring normal iron balance in the brain. As a result, it has a high potential for treating various kinds of atypical Parkinsonism. Recently, Alterity Therapeutics announced that the first patient has been enrolled in new Phase II clinical trial investigating ATH434 in individuals with multiple system atrophy (MSA), a type of atypical parkinsonism. The open-label, biomarker ATH434-202 research (NCT05864365) at Vanderbilt University Medical Centre in Tennessee is enrolling 15 persons with advanced MSA and clinical indications of parkinsonism. […] There are currently no treatments available to slow the progression of multiple system atrophys neurodegenerations. There are drugs available to help with multiple system atrophy symptoms, such as Levodopa, Amantadine, Droxidopa, Anticholinergic agents, and various off-label therapy.

• #108 Multiple System Atrophy: Causes and Treatment | Doctor

  https://patient.info/doctor/multiple-system-atrophy

  Minocycline: this is a tetracycline with neuroprotective efficacy in transgenic MSA mice which has shown some promise in the early stages of the disease in laboratory studies. […] Rasagiline: this is a monoamine-oxidase-B inhibitor which appears to have disease-modifying effects and is soon expected to enter phase 3 trials. […] Rifampicin: this has been shown to have the property of preventing -synuclein aggregation and so is also being considered as a therapeutic candidate.

• #109 Multiple System Atrophy | University of Michigan Health

  https://www.uofmhealth.org/conditions-treatments/brain-neurological-conditions/atrophy

  However, symptoms can be managed, which is why its important to be evaluated and treated by physicians who have experience dealing with MSA. […] Because there is no cure for MSA, treatment is focused on improving symptoms and quality of life. Treatment often includes medications to help control symptoms. Patients experiencing drops in blood pressure also receive dietary counseling, which helps them better regulate their blood pressure. […] We are also at the forefront of ongoing and groundbreaking research. One such example is a National Institutes of Health multi-center national clinical trial for the use of Rifampicin in treating MSA. The desired outcome is to determine whether the medication slows progression of the disease.

• #110 Emerging Therapies For Multiple System Atrophy Treatment

  https://www.delveinsight.com/blog/multiple-system-atrophy-treatment

  ENT-01 is an oral lab-made drug produced from squalamine, a substance identified in the liver and gall bladder of the dogfish shark. Preclinical studies suggest ENT-01s efficacy in removing harmful alpha-synuclein aggregates and preventing their development within gut nerve cells, hence boosting cells normal signaling. Recently on 24 May 2023, Enterin Inc. announced the FDAs acceptance of an investigator-sponsored Investigational New Drug (IND) application (166532) to treat a patient with prodromal multisystem atrophy (MSA) with ENT-01. Treatment will be continued continuously or until substantial adverse effects occur that necessitate drug withdrawal. […] Alteritys lead candidate, ATH434, is the first of a new generation of small molecules designed to block the aggregation of pathogenic proteins implicated in neurodegeneration. ATH434 decreases the aberrant accumulation of S and tau proteins in animal illness models by restoring normal iron balance in the brain. As a result, it has a high potential for treating various kinds of atypical Parkinsonism. Recently, Alterity Therapeutics announced that the first patient has been enrolled in new Phase II clinical trial investigating ATH434 in individuals with multiple system atrophy (MSA), a type of atypical parkinsonism. The open-label, biomarker ATH434-202 research (NCT05864365) at Vanderbilt University Medical Centre in Tennessee is enrolling 15 persons with advanced MSA and clinical indications of parkinsonism. […] There are currently no treatments available to slow the progression of multiple system atrophys neurodegenerations. There are drugs available to help with multiple system atrophy symptoms, such as Levodopa, Amantadine, Droxidopa, Anticholinergic agents, and various off-label therapy.

• #111 Treatment of multiple system atrophy – the past, present and future

  https://pmc.ncbi.nlm.nih.gov/articles/PMC6261842/

  Multiple system atrophy is a sporadic progressive degenerative disease which is characterized by multiple central nervous systems involved. So far, there is no effective medicine to cure MSA. The main research direction of treatment includes immunization transplantation and cytotherapy. […] Now there is no effective medicine to cure MSA, most part of methods are symptomatic treatment and enhanced care. The main research direction of treatment includes immunization transplantation and cytotherapy. […] In recent years, many kinds of stem cells have been found by researchers and they are trying to treat MSA and other degenerative diseases which hope to relieve the degeneration of neurons. […] Stem cell as universal cell has significant superiority in treatment of neurodegenerative diseases because of its particular biological characteristic.

• #112 Multiple System Atrophy: Advances in Diagnosis and Therapy

  https://www.e-jmd.org/journal/view.php?number=416

  Autologous MSCs are expected to modulate neuroinflammation, inhibit cell death and intercellular transmission, promote neurogenesis and autophagy, degrade -synuclein aggregates, stabilize axonal transport and phagocytose -synuclein by microglia. […] Other treatments, such as the mammalian target of rapamycin inhibitor sirolimus, which induces autophagy, were ineffective after 48 weeks of treatment. […] Another retrospective natural history study revealed that patients with MSA treated with SSRIs showed a better prognosis than untreated patients. […] Further studies are needed to determine whether serotonin-targeted therapy alleviates several symptoms and modifies the disease course of MSA.

• #113 Treatment of multiple system atrophy – the past, present and future

  https://pmc.ncbi.nlm.nih.gov/articles/PMC6261842/

  In a mice trial, the bone marrow MSCs were transplanted into the MSA-P type mice, the Parkinsonism symptoms got improved because of the neuroprotective and immune-regulation effects. […] In a recent study, the MSCs were injected into the internal carotid artery of MSA animal mode to observe the security and effectivity, and the results were that there was no ischemic changes in brain MRI, and in the treatment group, the survival amount of neurons in striatum and substantia nigra increased significantly and dyskinesia symptoms relieved obviously, which indicates that this method could be safe and effective. […] The basic research found that MSCs also have secretion ability. […] It indicates that MSCs not only can differentiate into and replace the damaged nerve cells, but have secretion and secretagogue function.

• #114 Treatment of multiple system atrophy – the past, present and future

  https://pmc.ncbi.nlm.nih.gov/articles/PMC6261842/

  Human umbilical cord blood is the residue of blood in the placenta and umbilical cord after fetal delivery. […] The researches about hUCB-MNC treatment on -synucleinisopathies diseases such as Parkinson disease, dementia and MSA, or on neuron motor disease increased gradually. […] It is important to choose the appropriate way of stem cell transplantation treatment for MSA. […] This method has been used safely and reliably in clinic for more than 20 years. In 2011, Professor Gong transplanted stem cells into the brain by lateral atlanto-occipital space puncture. […] More than 200 kinds of refractory nerve system diseases have been treated by this method, which included more than 30 cases of MSA with fine clinical effect and without serious complications. It indicates that stem cells treatment may be valid for refractory nerve system diseases. […] Stem cell has many characteristics such as self-replication, self-renewal, differentiation and secreting neurotrophic factors, and it can serve as a more effective intervention method for MSA and other refractory neurological diseases.

• #115 Treatment of multiple system atrophy – the past, present and future

  https://pmc.ncbi.nlm.nih.gov/articles/PMC6261842/

  In a mice trial, the bone marrow MSCs were transplanted into the MSA-P type mice, the Parkinsonism symptoms got improved because of the neuroprotective and immune-regulation effects. […] In a recent study, the MSCs were injected into the internal carotid artery of MSA animal mode to observe the security and effectivity, and the results were that there was no ischemic changes in brain MRI, and in the treatment group, the survival amount of neurons in striatum and substantia nigra increased significantly and dyskinesia symptoms relieved obviously, which indicates that this method could be safe and effective. […] The basic research found that MSCs also have secretion ability. […] It indicates that MSCs not only can differentiate into and replace the damaged nerve cells, but have secretion and secretagogue function.

• #116

  https://link.springer.com/article/10.1007/s00415-024-12269-5

  As previously stated, -synuclein-positive GCI is the pathological hallmark of MSA, nevertheless the absence of endogenous oligodendroglial -synuclein expression obscured the pathological detail. Targeting the misfolding and aggregation of -synuclein has always been one of the major treatment strategies for MSA. […] There was growing evidence that brain inflammation played a crucial role in the pathogenesis of MSA. […] The goal of neuroprotection treatment is to provide the brain with the necessary factors to support the neurons and to prevent neurodegenerative changes at the molecular level. […] The only clinical trial with positive outcomes is a trial of mesenchymal stem cells (MSC) treatment. […] However, because it was common to observe small ischemic lesions using magnetic resonance imaging (MRI) following intra-arterial infusion, safety concerns were raised to MSC therapies. […] In conclusion, MSA is a mostly sporadic disease. Up to date, it still has been difficult to identify the disease initiators and to investigate the core pathological mechanisms. But a growing number of evidences showed that MSA has a genetic component.

• #117 Tackling Multiple System Atrophy—with a virus | Ohio State College of Medicine

  https://medicine.osu.edu/news/tackling-multiple-system-atrophy

  Researchers at The Ohio State University College of Medicine have received FDA approval for the worlds first gene therapy clinical trial to treat multiple system atrophy (MSA). […] There is currently no cure or specific treatment for MSA, and symptomatic medications used for Parkinsons are often ineffective for patients with MSA. […] For the upcoming trial, researchers will insert into patients brains a genetically modified virus containing the DNA to produce GDNF. […] Researchers hope to see positive changes in patients within 12 months, including slowing of the diseases progression and reversal of Parkinsonian symptoms. […] Based on prior use of the identical agent and therapeutic approaches in humans with Parkinsons disease, participants in the new study face relatively low risk compared to the potential benefit of prolonged survival and enhanced quality of life, Dr. Merola says.

• #118 First Patient Dosed in Phase 1 Trial of Gene Therapy AB-1005 in Multiple System Atrophy-Parkinsonian Type

  https://www.neurologylive.com/view/first-patient-dosed-phase-1-trial-gene-therapy-ab-1005-multiple-system-atrophy-parkinsonian-type

  The double-blind, placebo-controlled study is expected to include 9 patients aged 35-75 years old with MSA-parkinsonian type who will be randomized 2:1 to either investigational AB-1005 or sham surgery. […] According to an announcement from AskBio, the first patient has been dosed in its phase 1 REGENERATE MSA-101 study (NCT04680065) assessing AB-1005, an adeno-associated viral vector serotype 2 (AAV2) gene therapy in development for patients with multiple system atrophy (MSA)-parkinsonian type (MSA-P). […] AB-1005, also known as AAV2-GDNF, is designed to encode the human glial cell line-derived neurotrophic factor (GDNF) transgene that is delivered to the putamen. […] There is no cure for MSA, and there are currently no treatments to stop or slow the progression of the disease. […] The trial will assess a number of secondary outcomes as well, including MSA symptoms and signs, through the Unified Multiple System Atrophy Rating Scale (UMSARS), and change in striatal dopamine transporter (DaT) binding, using Single Photon Emission Computed Tomography DaT imaging.

• #119 Gene Therapy For Multiple System Atrophy (MSA) | AskBio

  https://www.askbio.com/genetic-disease-focus/multiple-system-atrophy/

  We are now enrolling patients with the parkinsonian subtype of MSA (MSA-P) to assess the safety, tolerability and preliminary efficacy of AB-1005 gene therapy for this rapidly progressing condition. […] By enhancing levels of glial cell line-derived neurotrophic factor (GDNF), a naturally occurring growth factor in the brain, AB-1005 gene therapy is intended to promote the survival and functioning of vulnerable dopamine-producing brain cells that are sick but not dead in MSA-P. Taking advantage of the brains own cellular production, the therapeutic is designed to encourage natural growth of dopamine cells with a goal to restore continuous production of GDNF protein, necessary for the recipient nerve cells to trigger healthy body movement and various functions. The proposed gene therapy, AB-1005, may provide an advantage over intermittent protein infusions of synthetic GDNF, where brain levels may become lower than effective levels between infusions.

• #120 Emerging Therapies For Multiple System Atrophy Treatment

  https://www.delveinsight.com/blog/multiple-system-atrophy-treatment

  Theravance Biopharmas ampreloxetine is a once-daily Norepinephrine Reuptake Inhibitor (NRI) in development for the treatment of patients with symptomatic neurogenic orthostatic hypotension (nOH). It binds to norepinephrine transporters with a high affinity. Ampreloxetine increases extracellular norepinephrine concentrations by inhibiting the activity of these transporters. Based on the clinical trial outcomes, SEQUOIA, REDWOOD, and OAK, TD-9855 does not now hold a strong position as an emerging player. However, based on the predicted safety and efficacy outcomes of the investigational drug from the updated Phase III clinical trial slated for 2023, this investigational medicine is projected to validate as a potent cure in MSA patients considering the symptomatic neurogenic nOH treatment. […] Brain Neurotherapy Bio, Inc.s AAV2-GDNF Gene Therapy began a Phase I trial to assess the safety and potential clinical benefit of AAV2-GDNF given to the putamen in participants with a possible or likely diagnosis of MSA. GDNF gene therapy enhances the survival and function of susceptible dopamine-producing brain cells sick but not dead in MSA-P by increasing levels of the Glial cell line-derived Neurotrophic Factor (GDNF), a naturally occurring growth factor in the brain. Using the brains cellular machinery, the suggested gene therapy offers continuous creation and release of GDNF, which supports dopaminergic neuronal health. It may be preferable to intermittent protein infusions of synthetic GDNF, in which brain levels may become subtherapeutic between infusions.

• #121 Tackling Multiple System Atrophy—with a virus | Ohio State College of Medicine

  https://medicine.osu.edu/news/tackling-multiple-system-atrophy

  Researchers at The Ohio State University College of Medicine have received FDA approval for the worlds first gene therapy clinical trial to treat multiple system atrophy (MSA). […] There is currently no cure or specific treatment for MSA, and symptomatic medications used for Parkinsons are often ineffective for patients with MSA. […] For the upcoming trial, researchers will insert into patients brains a genetically modified virus containing the DNA to produce GDNF. […] Researchers hope to see positive changes in patients within 12 months, including slowing of the diseases progression and reversal of Parkinsonian symptoms. […] Based on prior use of the identical agent and therapeutic approaches in humans with Parkinsons disease, participants in the new study face relatively low risk compared to the potential benefit of prolonged survival and enhanced quality of life, Dr. Merola says.

• #122 Emerging Therapies For Multiple System Atrophy Treatment

  https://www.delveinsight.com/blog/multiple-system-atrophy-treatment

  Theravance Biopharmas ampreloxetine is a once-daily Norepinephrine Reuptake Inhibitor (NRI) in development for the treatment of patients with symptomatic neurogenic orthostatic hypotension (nOH). It binds to norepinephrine transporters with a high affinity. Ampreloxetine increases extracellular norepinephrine concentrations by inhibiting the activity of these transporters. Based on the clinical trial outcomes, SEQUOIA, REDWOOD, and OAK, TD-9855 does not now hold a strong position as an emerging player. However, based on the predicted safety and efficacy outcomes of the investigational drug from the updated Phase III clinical trial slated for 2023, this investigational medicine is projected to validate as a potent cure in MSA patients considering the symptomatic neurogenic nOH treatment. […] Brain Neurotherapy Bio, Inc.s AAV2-GDNF Gene Therapy began a Phase I trial to assess the safety and potential clinical benefit of AAV2-GDNF given to the putamen in participants with a possible or likely diagnosis of MSA. GDNF gene therapy enhances the survival and function of susceptible dopamine-producing brain cells sick but not dead in MSA-P by increasing levels of the Glial cell line-derived Neurotrophic Factor (GDNF), a naturally occurring growth factor in the brain. Using the brains cellular machinery, the suggested gene therapy offers continuous creation and release of GDNF, which supports dopaminergic neuronal health. It may be preferable to intermittent protein infusions of synthetic GDNF, in which brain levels may become subtherapeutic between infusions.

• #123 Multiple System Atrophy Research Program | NYU Langone Health

  https://med.nyu.edu/departments-institutes/neurology/research/divisions-centers/autonomic-disorders/multiple-system-atrophy-research-program

  We continue to have a number of clinical trial opportunities that are open to patients with MSA according to their specific needs. […] We are currently testing ampreloxetine, a new drug for orthostatic hypotension specifically designed for people with MSA. […] We are also conducting studies to test possible disease modifying treatments by using antibodies to remove abnormal alpha-synuclein, a protein thought to mediate disease progression in MSA and Parkinsons disease. This may be done by injecting the antibodies (TAK-341 and AMULET studies for MSA), or by using a vaccine to help the body produce these antibodies (UB-312 for MSA and Parkinsons disease).

• #124 Treatment of multiple system atrophy using intravenous immunoglobulin | BMC Neurology | Full Text

  https://bmcneurol.biomedcentral.com/articles/10.1186/1471-2377-12-131

  Multiple system atrophy (MSA) is a progressive neurodegenerative disorder of unknown etiology, manifesting as combination of parkinsonism, cerebellar syndrome and dysautonomia. Disease-modifying therapies are unavailable. […] This pilot clinical trial evaluated safety and tolerability of intravenous immunoglobulin (IVIG) in MSA. […] Treatment with IVIG appears to be safe, feasible and well tolerated and may improve functionality in MSA. A larger, placebo-controlled study is needed. […] Pharmacological management remains limited, and at present, there are no therapies that modify disease progression. […] IVIG has anti-inflammatory properties with multiple mechanisms of action. IVIG inhibits autoreactive T cells, suppresses autoantibodies through anti-idiotypic interactions and interferes with the production of cytokines.

• #125 Multiple System Atrophy: Causes and Treatment | Doctor

  https://patient.info/doctor/multiple-system-atrophy

  Minocycline: this is a tetracycline with neuroprotective efficacy in transgenic MSA mice which has shown some promise in the early stages of the disease in laboratory studies. […] Rasagiline: this is a monoamine-oxidase-B inhibitor which appears to have disease-modifying effects and is soon expected to enter phase 3 trials. […] Rifampicin: this has been shown to have the property of preventing -synuclein aggregation and so is also being considered as a therapeutic candidate.

• #126 Multiple System Atrophy: Causes and Treatment | Doctor

  https://patient.info/doctor/multiple-system-atrophy

  Minocycline: this is a tetracycline with neuroprotective efficacy in transgenic MSA mice which has shown some promise in the early stages of the disease in laboratory studies. […] Rasagiline: this is a monoamine-oxidase-B inhibitor which appears to have disease-modifying effects and is soon expected to enter phase 3 trials. […] Rifampicin: this has been shown to have the property of preventing -synuclein aggregation and so is also being considered as a therapeutic candidate.

• #127 Current Management and Emerging Therapies in Multiple System Atrophy

  https://pmc.ncbi.nlm.nih.gov/articles/PMC7851250/

  To date there are no approved disease-modifying therapies for MSA; thus, treatment is focused mainly on symptom management tailored to the specific patient and importantly involves a multidisciplinary approach with rehab and other allied healthcare partners. […] Parkinsonism, dystonia, spasticity, dysarthria, dysphagia, autonomic failure, and sleep disorders are common symptoms that require tailored symptomatic management. […] While ideal, multidisciplinary care for MSA and other neurodegenerative disorders faces challenges in delivery. […] Current care models are often plagued by a lack of patient-centered care with poor continuity and delayed or reactive care delivery. […] The focus on synuclein has resulted in several trials targeting synuclein pathology through inhibition of aggregation, enhancement of degradation, or immunotherapy.

• #128

  https://link.springer.com/article/10.1007/s13311-020-00890-x

  Multiple system atrophy (MSA) is a progressive neurodegenerative disease variably associated with motor, nonmotor, and autonomic symptoms, resulting from putaminal and cerebellar degeneration and associated with glial cytoplasmic inclusions enriched with -synuclein in oligodendrocytes and neurons. […] Although symptomatic treatment of MSA can provide significant improvements in quality of life, the benefit is often partial, limited by adverse effects, and fails to treat the underlying cause. […] Treatment is best achieved through a coordinated multidisciplinary approach driven by the patients priorities and goals of care. […] Research into disease-modifying therapies is ongoing with a particular focus on synuclein-targeted therapies among others. […] There are currently no approved disease-modifying therapies, although research in a variety of mechanistically driven areas is ongoing and the patient should be given the opportunity to participate in clinical trials.

• #129 Multiple system atrophy | Monash Health

  https://monashhealth.org/services/movement-disorders-program/understanding-movement-disorders/multiple-system-atrophy/

  Currently there is no treatment available to stop or slow the progression of MSA. […] There are, however, a variety of medical treatments and therapies available to manage the symptoms. […] A multidisciplinary team that includes a neurologist and therapists who specialise in movement disorders is recommended for the management of the complex MSA symptoms. The appropriate multidisciplinary team members should be seen from the time the diagnosis of MSA is received. […] A neurologist specialised in movement disorders can advise on medical treatments to treat the presenting symptoms. […] The symptoms of slow movement and rigidity that occur in MSA may improve in the early stages with the use of PD medications, especially levodopa preparations such as sinemet or madopar. […] Botulinum toxin A may be useful in treating troublesome dystonia.

• #130 Multiple System Atrophy (MSA) Treatments | Multiple System Atrophy | UT Southwestern Medical Center

  https://utswmed.org/conditions-treatments/multiple-system-atrophy/multiple-system-atrophy-msa-treatments/

  Medication might also be used to treat: Bladder dysfunction, Blood pressure fluctuation, Dystonia (involuntary muscle contractions), REM behavior disorder (acting out dreams when asleep), Mood disorders. […] UT Southwesterns neurorehabilitation program, which includes physical, speech, and occupational therapy, can ease symptoms and help patients maintain as much motor and muscle capacity as possible as MSA progresses. Therapists also provide family members with information to help them be part of the patients successful rehabilitation. […] A speech-language pathologist can help treat voice, speech, drooling, and swallowing problems. […] Depending on a patients needs, evaluation and treatment might be performed by specialists from a range of other disciplines, such as: Autonomic experts, Cardiovascular physicians, Nutritionists, Otolaryngologists, Palliative care physicians, Sleep specialists, Pulmonary specialists, Urologists. […] The team at the UT Southwestern Movement Disorders Clinic helps coordinate these specialty services and follows up with patients with MSA and their caregivers throughout the course of the illness.

• #131 Multiple System Atrophy

  https://neurosciences.ucsd.edu/centers-programs/movement-disorders/community/disease-overview/msa.html

  When these measures are insufficient, medications such as fludrocortisone that retain salt, or midodrine that increase the blood pressure may be needed. […] Bladder function should be evaluated by a urologist, usually requiring a urodynamic study that allows the physician to better manage the „neurogenic bladder.” If the bladder tends to be hyperactive with increased frequency of urination, medications (such as oxybutynin and tolterodine) can help to decrease frequency and urgency symptoms and improve bladder control. […] REM sleep behavioral disorder symptoms can be treated by melatonin, a natural hormone in the human body that is available over the counter. When melatonin is not effective, other therapies could be tried such as gabapentin or clonazepam. […] To improve obstructive sleep apnea, a machine that provides positive pressure ventilation with either a Continuous Positive Airway Pressure (CPAP) or Bilevel Positive Airway Pressure (BiPAP) system may be needed.

• #132 Multiple System Atrophy (MSA) Treatments | Multiple System Atrophy | UT Southwestern Medical Center

  https://utswmed.org/conditions-treatments/multiple-system-atrophy/multiple-system-atrophy-msa-treatments/

  Medication might also be used to treat: Bladder dysfunction, Blood pressure fluctuation, Dystonia (involuntary muscle contractions), REM behavior disorder (acting out dreams when asleep), Mood disorders. […] UT Southwesterns neurorehabilitation program, which includes physical, speech, and occupational therapy, can ease symptoms and help patients maintain as much motor and muscle capacity as possible as MSA progresses. Therapists also provide family members with information to help them be part of the patients successful rehabilitation. […] A speech-language pathologist can help treat voice, speech, drooling, and swallowing problems. […] Depending on a patients needs, evaluation and treatment might be performed by specialists from a range of other disciplines, such as: Autonomic experts, Cardiovascular physicians, Nutritionists, Otolaryngologists, Palliative care physicians, Sleep specialists, Pulmonary specialists, Urologists. […] The team at the UT Southwestern Movement Disorders Clinic helps coordinate these specialty services and follows up with patients with MSA and their caregivers throughout the course of the illness.

• #133 Multiple system atrophy | Monash Health

  https://monashhealth.org/services/movement-disorders-program/understanding-movement-disorders/multiple-system-atrophy/

  There are currently no medications that can reverse or slow down the cognitive changes that occur with MSA. […] A physiotherapist specialised in movement disorders such as MSA can assess walking and balance problems and recommend ways to improve mobility and safety. […] An occupational therapist specialised in movement disorders such as MSA can assess the person at home and suggest ways to improve safety, both inside and outside the home. […] A speech pathologist specialised in movement disorders such as MSA can assess speech and swallowing difficulties and teach strategies to improve them. […] A dietitian specialised in movement disorders such as MSA can assess the persons diet and provide them with suggested menus to improve any dietary problems they may have. […] A social worker specialised in movement disorders such as MSA can assist the person with MSA, their caregiver and family negotiate the challenges faced across the life time of the persons condition.

• #134 Multiple System Atrophy | University of Michigan Health

  https://www.uofmhealth.org/conditions-treatments/multiple-system-atrophy

  There is no cure, and many physicians are not familiar with the condition meaning MSA is often misdiagnosed. However, symptoms can be managed, which is why its important to be evaluated and treated by physicians who have experience dealing with MSA. […] Because there is no cure for MSA, treatment is focused on improving symptoms and quality of life. Treatment often includes medications to help control symptoms. Patients experiencing drops in blood pressure also receive dietary counseling, which helps them better regulate their blood pressure. Sometimes medications are necessary for fainting episodes. We also work closely with urologists to treat patients who are experiencing urinary difficulties. Because a diagnosis can be life-changing, our patients also have access to U-Ms psychiatrists and counselors, who will help both the patient and family members cope with the disease. […] The University of Michigan Atypical Parkinsonian Clinic was created in the summer of 2020 to promote up-to-date and comprehensive clinical care and access to research for those patients and families with diseases such as MSA.

• #135 Multiple System Atrophy (MSA) – Brain, Spinal Cord, and Nerve Disorders – Merck Manual Consumer Version

  https://www.merckmanuals.com/home/brain-spinal-cord-and-nerve-disorders/autonomic-nervous-system-disorders/multiple-system-atrophy-msa

  A high-fiber diet and stool softeners are recommended. If constipation persists, enemas may be necessary. […] Usually, treatment consists of medications such as sildenafil, tadalafil, vardenafil, or avanafil, taken by mouth. However, these medications may make orthostatic hypotension worse. […] Physical, occupational, and speech therapists can teach people ways to compensate when walking, doing daily activities, and speaking become difficult. Specialists in palliative medicine focus on relieving pain and treating symptoms and helps people deal with end-of-life issues. Social workers can help people find support groups and, when symptoms become disabling, home health care or hospice services.

• #136 Multiple System Atrophy (MSA) – Brain, Spinal Cord, and Nerve Disorders – Merck Manual Consumer Version

  https://www.merckmanuals.com/home/brain-spinal-cord-and-nerve-disorders/autonomic-nervous-system-disorders/multiple-system-atrophy-msa

  A high-fiber diet and stool softeners are recommended. If constipation persists, enemas may be necessary. […] Usually, treatment consists of medications such as sildenafil, tadalafil, vardenafil, or avanafil, taken by mouth. However, these medications may make orthostatic hypotension worse. […] Physical, occupational, and speech therapists can teach people ways to compensate when walking, doing daily activities, and speaking become difficult. Specialists in palliative medicine focus on relieving pain and treating symptoms and helps people deal with end-of-life issues. Social workers can help people find support groups and, when symptoms become disabling, home health care or hospice services.

• #137 Multiple system atrophy | Monash Health

  https://monashhealth.org/services/movement-disorders-program/understanding-movement-disorders/multiple-system-atrophy/

  There are currently no medications that can reverse or slow down the cognitive changes that occur with MSA. […] A physiotherapist specialised in movement disorders such as MSA can assess walking and balance problems and recommend ways to improve mobility and safety. […] An occupational therapist specialised in movement disorders such as MSA can assess the person at home and suggest ways to improve safety, both inside and outside the home. […] A speech pathologist specialised in movement disorders such as MSA can assess speech and swallowing difficulties and teach strategies to improve them. […] A dietitian specialised in movement disorders such as MSA can assess the persons diet and provide them with suggested menus to improve any dietary problems they may have. […] A social worker specialised in movement disorders such as MSA can assist the person with MSA, their caregiver and family negotiate the challenges faced across the life time of the persons condition.

• #138 Next Era of Multiple System Atrophy Treatment

  https://www.delveinsight.com/blog/future-of-multiple-system-atrophy-treatment

  Although Ampreloxetine faced a setback when its Phase III, REDWOOD trial was terminated based on efficacy results, the company remains optimistic and has initiated another Phase III trial, called CYPRESS, following discussion with the FDA. […] These developments signal significant progress in targeting stage-specific MSA treatment pathways. […] The future of the MSA market is poised for transformation, driven by the increasing recognition of disease-modifying therapies and a focus on innovative treatment modalities. […] The dynamic pipeline, with numerous competitors developing innovative treatments, signals a shift towards more targeted, disease-modifying approaches. […] A comprehensive assessment of emerging drug assets in the pipeline for MSA treatment, along with detailed analyses, is available in the final report provided by DelveInsight.

• #139

  https://link.springer.com/article/10.1007/s13311-020-00890-x

  A relatively limited number of trials to date have failed to identify an effective disease-modifying therapy. […] The focus on synuclein has resulted in several trials targeting synuclein pathology through inhibition of aggregation, enhancement of degradation, or immunotherapy. […] Despite promising preclinical data and ongoing clinical trials in this area, caution is warranted given previous failed trials of drugs claiming a similar ability to affect -synuclein aggregation. […] Research has focused on the role of mitochondria in pathogenesis as well, with mitochondrial mutations and toxins playing a key role in striatonigral degeneration and parkinsonism in both animal models and patients. […] Increasing evidence suggests that the inflammatory response to abnormal -synuclein accumulation and aggregation plays a key role in the pathogenesis of MSA (and other synucleinopathies). […] Treatment of MSA remains a challenge and requires a multidisciplinary approach including allied healthcare providers, rehabilitation, and supportive care.

• #140 Treatment of multiple system atrophy – the past, present and future

  https://pmc.ncbi.nlm.nih.gov/articles/PMC6261842/

  Human umbilical cord blood is the residue of blood in the placenta and umbilical cord after fetal delivery. […] The researches about hUCB-MNC treatment on -synucleinisopathies diseases such as Parkinson disease, dementia and MSA, or on neuron motor disease increased gradually. […] It is important to choose the appropriate way of stem cell transplantation treatment for MSA. […] This method has been used safely and reliably in clinic for more than 20 years. In 2011, Professor Gong transplanted stem cells into the brain by lateral atlanto-occipital space puncture. […] More than 200 kinds of refractory nerve system diseases have been treated by this method, which included more than 30 cases of MSA with fine clinical effect and without serious complications. It indicates that stem cells treatment may be valid for refractory nerve system diseases. […] Stem cell has many characteristics such as self-replication, self-renewal, differentiation and secreting neurotrophic factors, and it can serve as a more effective intervention method for MSA and other refractory neurological diseases.

• #141 Multiple System Atrophy: Advances in Diagnosis and Therapy

  https://www.e-jmd.org/journal/view.php?number=416

  This review summarizes improvements in understanding the pathophysiology and early clinical symptoms of multiple system atrophy (MSA) and advancements in diagnostic methods and disease-modifying therapies for the condition. […] Symptomatic treatment has limited efficacy in MSA, and no treatments suppress or alleviate disease progression. However, notable advancements have been achieved in the development of antibody therapies against -synuclein, multitargeted disease-modifying therapies, including mesenchymal stem cell (MSC)-mediated neuroinflammation treatments, and other symptomatic treatments, such as selective serotonin reuptake inhibitors (SSRIs). […] Novel disease-modifying therapies for MSA are being developed to inhibit -synuclein aggregation, alleviate neuroinflammation and confer neuroprotective effects.

• #142

  https://link.springer.com/article/10.1007/s13311-020-00890-x

  A relatively limited number of trials to date have failed to identify an effective disease-modifying therapy. […] The focus on synuclein has resulted in several trials targeting synuclein pathology through inhibition of aggregation, enhancement of degradation, or immunotherapy. […] Despite promising preclinical data and ongoing clinical trials in this area, caution is warranted given previous failed trials of drugs claiming a similar ability to affect -synuclein aggregation. […] Research has focused on the role of mitochondria in pathogenesis as well, with mitochondrial mutations and toxins playing a key role in striatonigral degeneration and parkinsonism in both animal models and patients. […] Increasing evidence suggests that the inflammatory response to abnormal -synuclein accumulation and aggregation plays a key role in the pathogenesis of MSA (and other synucleinopathies). […] Treatment of MSA remains a challenge and requires a multidisciplinary approach including allied healthcare providers, rehabilitation, and supportive care.

• #143 Multiple System Atrophy | Peter O’Donnell Jr. Brain Institute | Condition | UT Southwestern Medical Center

  https://utswmed.org/conditions-treatments/multiple-system-atrophy/

  UT Southwestern Medical Center offers personalized treatment of multiple system atrophy (MSA) to maximize mobility and independence. […] UT Southwestern neurologists have specialized expertise in MSA and offer patients a multidisciplinary approach to treatment, including access to leading-edge therapies. […] For people who are diagnosed with MSA, physicians tailor treatment plans to each patients specific symptoms. Treatment options include medications, physical therapy, speech therapy, and other approaches. […] While there is no cure for MSA or specific treatments to slow its progression, research has brought us closer to identifying the cause of MSA, which is the first step toward finding a cure. […] UT Southwestern is currently conducting a longitudinal study to track the effect of integrated treatment on the quality of life of MSA patients and their families. Researchers are also in the process of starting new trials that will contribute to a better understanding of and treatment for MSA over the next decade.

• #144

  https://link.springer.com/article/10.1007/s13311-020-00890-x

  A relatively limited number of trials to date have failed to identify an effective disease-modifying therapy. […] The focus on synuclein has resulted in several trials targeting synuclein pathology through inhibition of aggregation, enhancement of degradation, or immunotherapy. […] Despite promising preclinical data and ongoing clinical trials in this area, caution is warranted given previous failed trials of drugs claiming a similar ability to affect -synuclein aggregation. […] Research has focused on the role of mitochondria in pathogenesis as well, with mitochondrial mutations and toxins playing a key role in striatonigral degeneration and parkinsonism in both animal models and patients. […] Increasing evidence suggests that the inflammatory response to abnormal -synuclein accumulation and aggregation plays a key role in the pathogenesis of MSA (and other synucleinopathies). […] Treatment of MSA remains a challenge and requires a multidisciplinary approach including allied healthcare providers, rehabilitation, and supportive care.

• #145 Current Management and Emerging Therapies in Multiple System Atrophy

  https://pmc.ncbi.nlm.nih.gov/articles/PMC7851250/

  Multiple system atrophy (MSA) is a progressive neurodegenerative disease variably associated with motor, nonmotor, and autonomic symptoms, resulting from putaminal and cerebellar degeneration and associated with glial cytoplasmic inclusions enriched with -synuclein in oligodendrocytes and neurons. […] Although symptomatic treatment of MSA can provide significant improvements in quality of life, the benefit is often partial, limited by adverse effects, and fails to treat the underlying cause. […] Research into disease-modifying therapies is ongoing with a particular focus on synuclein-targeted therapies among others. […] Currently available lab tests or imaging do not provide additional diagnostic or prognostic sensitivity or specificity beyond that of a thorough clinical assessment. […] There are currently no approved disease-modifying therapies, although research in a variety of mechanistically driven areas is ongoing and the patient should be given the opportunity to participate in clinical trials.

• #146 Risk willingness in multiple system atrophy and Parkinson’s disease understanding patient preferences | npj Parkinson’s Disease

  https://www.nature.com/articles/s41531-024-00764-5

  A systematic quantitative assessment of patients risk willingness and associated features may assist physicians in conducting individual consultations with patients who have MSA or PD by facilitating communication of risks and benefits of a treatment option. […] Involving patients preferences from the initial stages of therapy development has been increasingly pursued by regulatory agencies such as the US Food and Drug Administration and the European Medicines Agency. […] This study aimed to quantitatively assess the potential risks related to disease-modifying therapeutic options that patients with MSA and PD would be willing to accept in a clinical trial. […] MSA patients demonstrated a remarkable willingness, as indicated by their acceptance of a median 1% risk of sudden death for a median 99% probability of symptom cure. […] Our study has shown that analyses of therapy-associated risk willingness at group level cannot be representative of the whole patient population. […] Our findings underscore the necessity of a patient-centered approach in therapy development for MSA and PD.

• #147

  https://link.springer.com/article/10.1007/s13311-020-00890-x

  A relatively limited number of trials to date have failed to identify an effective disease-modifying therapy. […] The focus on synuclein has resulted in several trials targeting synuclein pathology through inhibition of aggregation, enhancement of degradation, or immunotherapy. […] Despite promising preclinical data and ongoing clinical trials in this area, caution is warranted given previous failed trials of drugs claiming a similar ability to affect -synuclein aggregation. […] Research has focused on the role of mitochondria in pathogenesis as well, with mitochondrial mutations and toxins playing a key role in striatonigral degeneration and parkinsonism in both animal models and patients. […] Increasing evidence suggests that the inflammatory response to abnormal -synuclein accumulation and aggregation plays a key role in the pathogenesis of MSA (and other synucleinopathies). […] Treatment of MSA remains a challenge and requires a multidisciplinary approach including allied healthcare providers, rehabilitation, and supportive care.

Zobacz więcej